WO2012096475A2 - Composition for a functional food having the effect of restoring blood composition and function - Google Patents

Composition for a functional food having the effect of restoring blood composition and function Download PDF

Info

Publication number
WO2012096475A2
WO2012096475A2 PCT/KR2012/000107 KR2012000107W WO2012096475A2 WO 2012096475 A2 WO2012096475 A2 WO 2012096475A2 KR 2012000107 W KR2012000107 W KR 2012000107W WO 2012096475 A2 WO2012096475 A2 WO 2012096475A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
functional food
health functional
blood
Prior art date
Application number
PCT/KR2012/000107
Other languages
French (fr)
Korean (ko)
Other versions
WO2012096475A3 (en
Inventor
이행우
신현철
김성호
현종훈
Original Assignee
주식회사 보타메디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 보타메디 filed Critical 주식회사 보타메디
Priority to CN201280005658.0A priority Critical patent/CN103384477B/en
Publication of WO2012096475A2 publication Critical patent/WO2012096475A2/en
Publication of WO2012096475A3 publication Critical patent/WO2012096475A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
    • A23L29/281—Proteins, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a health functional food composition effective to restore health by restoring abnormal blood levels and functions caused by anti-cancer treatment and surgery, chronic disease, excessive exercise stress or aging.
  • 5-FU The chemotherapeutic agent 5-fluorouracil
  • 5-FU is an anticancer agent that inhibits thymidylate synthase by converting into active nucleotides in cancer cells and inhibits the synthesis of DNA of cells, and is clinically used for breast cancer, colon cancer, rectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, liver cancer, head and neck cancer and bladder cancer. It is widely used and is also used topically for skin cancer.
  • hematopoietic toxicity is known as a representative side effect, and other side effects of gastrointestinal side effects such as severe gastritis, esophagitis, proctitis, and diarrhea are high and skin hyperpigmentation is known.
  • 5-FU is known to cause hematopoietic toxicity, such as a decrease in white blood cell counts, decreased intestinal mucosal sucrase activity, digestive toxicity, such as diarrhea induction, spleen weight loss, and lymphocyte reduction.
  • chemotherapeutic agents include adriamycin, bleomycin, mitomycin, cisplatin, and their long-term administration of DNA synthesis, cell division inhibition, and cell membrane damage. And can cause reversible or irreversible side effects from DNA damage.
  • Chemotherapy used to treat cancer, aims to kill cancer cells with rapid division, but at the same time destroys normal cells with rapid division such as blood cells. Therefore, the most representative and common sequelae of chemotherapy-based chemotherapy is a blood dysfunction due to the destruction of blood cells. For example, thrombocytopenia, reduced white blood cell count, and reduced immunity are typical phenomena that harm health and often deteriorate quality of life.
  • the general recovery formula consists only of abundant supply of essential nutrients or antioxidants, or consists of food ingredients whose chemical composition is unknown (Korean Patent Nos. 0722698, 0591539, and 0355012).
  • Herbal medicine composition has been shown to show a tendency to restore white blood cells, red blood cells, platelets and immunity, but it does not show an effect on the recovery of antioxidant defenses, which is an important indicator of health recovery, and as an herbal medicine composite composition There is a limit to the difficulty of clear standardization and the general application as a food.
  • the present inventors have studied the characteristics of various components from a nutritional, oriental medical and biochemical point of view in order to develop a food composition that effectively achieves the recovery of blood composition and function, and thus, the components of the blood, blood
  • the present invention has been completed by evaluating specific combinations of components that promote the production of oxidants, components that remove inflammatory factors in the blood, and components that promote the antioxidant function of the blood, and effects thereof, thereby completing the present invention.
  • An object of the present invention for overcoming the above limitations collagen 30 to 90% by weight, flaxseed 3 to 60% by weight, fluorotannin 1 to 50% by weight, calcium 1 to 30% by weight, iron 0.1 to 3% by weight
  • a health functional food composition comprising 0.01 to 0.5% by weight of vitamin E and 0.01 to 0.1% by weight of vitamin B.
  • the present invention also provides a health functional food comprising 1 to 1000 parts by weight of an excipient component with respect to 100 parts by weight of such a health functional food composition.
  • the present invention is 30 to 90% by weight of collagen, 3 to 60% by weight flaxseed, 1 to 50% by weight of phlorotannin, 1 to 30% by weight of calcium, 0.1 to 3% by weight of iron, 0.01 to 0.5% by weight of vitamin E and vitamin B It provides a health functional food composition comprising 0.01 to 0.1% by weight.
  • the present invention provides a health functional food composition that can be used in the case of anti-cancer treatment process before and after, before and after surgery, limb disease, excessive exercise, excessive mental stress or physical degradation due to aging.
  • the present invention provides in the form of tablets, capsules, pills, granules, liquid formulations, beverages, liquid, porridge, bread, bars and cookies so as to conveniently consume such a health food composition.
  • the present invention also provides a health functional food comprising 1 to 1000 parts by weight of the excipient component with respect to 100 parts by weight of the composition for health functional food as described above.
  • Ingestion of the health functional food composition of the present invention can improve blood composition abnormality and dysfunction due to drugs, stress conditions, etc., can restore blood composition or antioxidant function to a normal value.
  • the present invention is 30 to 90% by weight of collagen, 3 to 60% by weight flaxseed, 1 to 50% by weight of phlorotannin, 1 to 30% by weight of calcium, 0.1 to 3% by weight of iron, 0.01 to 0.5% by weight of vitamin E and vitamin B It provides a health functional food composition comprising 0.01 to 0.1% by weight.
  • Collagen is a light protein constituting animal bones, cartilage, fish scales and the like. It is present as a fibrous solid and insoluble in water but becomes gelatin when dissolved.
  • Proline amino acid includes proline, oxyproline, glycine and the like. It is a rich source of protein for the production of blood and helps to produce albumin and immunoglobulin in the blood. In the present invention, when the collagen is included to less than 30% by weight or more than 90% by weight, the effect is halved or economically unsuitable.
  • Collagen used in the present invention is derived from fish or meat, but is not limited thereto.
  • Flax is a perennial plant of the dicotyledonous rat, Ratus Arachnid, distributed in Europe and Argentina. Flax seeds are rich in phytoestrogens, lignans and plant proteins, which help to make albumin and globulin, which is good for boosting human immunity. In the present invention, when the flaxseed is included in less than 3% by weight is less effective, if it exceeds 60% by weight it is difficult to make the desired formulation.
  • Flaxseed used in the present invention may be used as a powder or a liquid, but is not limited thereto.
  • Phlorotannin is a kind of tannin that exists in brown algae and the like and is a powerful antioxidant in the middle region of water-soluble and fat-soluble. Recently, many studies on the restoration of blood vessel function and the removal of inflammatory factors have been published.
  • the phlorotannin used in the present invention is preferably ecol, dieckol, 6,6'-bieckol, 8,8'-bieckol (8,8). '-bieckol), 2-O- (2,4,6-trihydroxyphenyl) -6,6'-biechol (2-O- (2,4,6-trihydroxyphenyl) -6,6'-bieckol ), Phloofucofuroeckol, fucofuroeckol, 2-phloroeckol, 7-phloroeckol, triplehlorethol, floh One or two or more mixtures selected from the group consisting of rotannin A (phlorotannin A), but is not limited thereto.
  • the effect when the phlorotannin is included in less than 1% by weight, the effect is inferior.
  • Calcium is an alkaline earth metal corresponding to atomic number 19 on the periodic table, and is an important mineral for regulating basic activities of the body such as blood coagulation and muscle contraction. It is the most nutrient deficient in the diet, and the recommended daily intake reaches 700 mg in adults.
  • the calcium when the calcium is included in less than 1% by weight is less effective, if it exceeds 30% by weight it is difficult to make a formulation.
  • Iron is a metal corresponding to atomic number 26 in the periodic table, which is an essential mineral in the physiological process of oxygen transport and cellular respiration. It is essential for red blood cell production. For adult women, the recommended daily intake is 12-15 mg.
  • the effect when the iron is included in less than 0.1% by weight, the effect is reduced and when the content exceeds 3% by weight it is difficult to make the desired formulation or adversely affect the color, shelf life of the formulation.
  • Vitamin E is called tocopherol and acts as an antioxidant as a fat-soluble vitamin.
  • vitamin E when included in less than 0.01% by weight, the effect is reduced, and when it exceeds 0.5% by weight, there is concern of toxicity.
  • Vitamin B is present in several subtypes, immune system and metabolism promoting action. In the present invention, if the vitamin B is included in less than 0.01% by weight, the effect is reduced, while exceeding 0.1% by weight adversely affects the shelf life of the formulation.
  • composition according to the present invention is 30 to 90% by weight of collagen, 3 to 60% by weight of flaxseed, 1 to 50% by weight of phlorotannin, 1 to 30% by weight of calcium, 0.1 to 3% by weight of iron, 0.01 to 0.5% by weight of vitamin E.
  • a dietary supplement composition comprising% and 0.01 to 0.1% by weight of vitamin B, 1 to 10% by weight of lecithin, 0.005 to 3% by weight of lignan, and 0.01 to 0.2% by weight of copper may be further included.
  • Lecithin is one of the phospholipids containing glycerin phosphoric acid and is a major component of the biofilm, which is found in egg yolk, soybean oil, liver and brain.
  • Lignan is a generic term for natural products in which n-phenylpropane is a two-molecule bond in the ß site of the n-propyl side chain. It is also an antioxidant and phytoestrogens.
  • Copper is a metal with atomic number 29 in the periodic table that aids in the use of iron and in the synthesis of red blood cells. For adults, the recommended daily intake is 1.5 to 3 mg.
  • the side effect inhibitory effect was evaluated, and the administration of the composition according to the present invention significantly increased platelet, leukocyte, and red blood cell levels, and immunity.
  • the administration of the composition according to the present invention Leukocytes, red blood cells, hemoglobin and red blood cell volume levels were elevated.
  • the health functional food composition according to the present invention can be seen to restore the blood composition to the normal value.
  • the representative antioxidant substance in the blood Glutathione, catalase and malondialdehyde (MDA), a lipid peroxidation agent that indicates the degree of oxidative stress in the blood, were measured, respectively.
  • MDA malondialdehyde
  • the health functional food composition according to the present invention restores the antioxidant function of blood to a normal value.
  • Health functional food composition according to the present invention can be used in the case of anti-cancer treatment process before and after, before and after surgery, chronic disease, excessive exercise, excessive mental stress or physical strength decline due to aging, but is not limited thereto.
  • the health functional food composition according to the present invention may be prepared in the form of tablets, capsules, pills, liquid granules, beverages, liquid, porridge, bread, bars, and cookies for convenience, but is not limited thereto.
  • the present invention provides a health functional food comprising 1 to 1000 parts by weight of excipient components based on 100 parts by weight of the composition for health functional food.
  • the excipients are glutinous rice, spicy rice, wheat flour, honey, crystalline cellulose, silicon dioxide, fructose, anhydrous citric acid, inulin, vitamin C, sesame oil, soy sauce, butter, yeast, salt, sugar, starch, gelatinized starch, microcrystalline cellulose, Lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, sodium starch glycolate, carnauba lead, Synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, dextrose, sorbitol, talc and the like may be used, but is not limited thereto.
  • the excipient component is preferably included 1 to 1000 parts by weight based on the composition, but is not limited thereto.
  • a composition was prepared in which the content of each component was varied.
  • composition 1 Composition 2
  • Composition 3 Composition 4
  • Composition 5 Composition 6
  • Composition 7 Composition 8
  • Composition 9 Composition 10
  • Collagen 40 60 80 65 60
  • Flaxseed powder 40 20 5 16 18 18 24 12 5 18 Phlorotannin 5 5 5 28 25 7 10 20 35 7 calcium 10
  • 10 5 14 12 14 12 12 4 14 iron 1.5 1.5 1.5 1.5 0.8 0.5 0.75 0.7 0.7 0.2 0.75 Vitamin E 0.35 0.2 0.2 0.275 0.25 0.1 0.2 0.05 0.3 0.1 Vitamin B 0.075 0.05 0.05 0.04 0.015 0.075 0.05 0.2 0.05 0.15 lecithin 3 3 3
  • the health functional food composition according to the present invention can be formulated and ingested through the following method.
  • Glutinous rice, flour, honey, water is mixed in a weight ratio of 1: 1: 0.5: 3, boiled and cooled to room temperature to make a paste.
  • the resulting paste: composition 1 is kneaded in a weight ratio of 1: 9 to prepare 2 g of each ring. Two pills (4 g) per day are eaten after chewing.
  • Composition 2 lactose, crystalline cellulose, silicon dioxide and magnesium stearate are mixed in a weight ratio of 35: 25: 37: 1: 1 and then tableted (600 mg) is prepared using a tablet press. Take 6-10 tablets daily.
  • Composition 4 fructose, citric anhydride, inulin, vitamin C and water are mixed in a weight ratio of 2: 8: 1: 8: 0.2: 160, and then boiled with stirring for 5 minutes and then cooled. Take 180 mL of drink twice daily.
  • composition 9 250 g of wheat flour, 30 g of butter, 6.5 g of yeast, 5 g of salt, 37.5 g of sugar, 130 g of water, 20 g of composition 9 were mixed and kneaded firstly at 37 ° C., and then divided into 30 g each. List them in a pan and, after the second fermentation, loosen the eggs on the swelled top and apply them. Bake at oven temperature 180 ° C. for 15 minutes. Take it as a meal replacement or snack 2 or 3 times a day.
  • composition 2 After mixing Composition 2 and magnesium stearate in a weight ratio of 99.8: 0.2, the hard capsule (gelatin component) is filled with 450 mg of each, and 3-9 capsules are taken daily.
  • Brown rice powder, brown seaweed powder, carrot juice, apple juice, salt, composition 10 and water are mixed at a weight ratio of 5: 1: 10: 10: 0.1: 2: 200, boiled and cooled to room temperature. Put it in a plastic bag with a tube and take it according to the patient's condition.
  • the finished dough is filled with a volume of about 70% in a silver foil frame 3 cm wide, 9 cm long, and 2 cm deep, and baked in an oven at 180 ° C. for 15 minutes. Take two or three snacks a day.
  • 5-FU 5-fluorouracil
  • B16-BL6 melanoma cells were injected subcutaneously in a volume of 0.1 ml of 5 ⁇ 10 5 to 1 ⁇ 10 6 cells per mouse. After 7 days, it was confirmed that a distinct tumor was formed on the skin, and each mouse was intraperitoneally administered once with 5-FU, and then the composition 4 of Preparation Example 1 was once daily for 7 days at 70 mg / kg body weight (sonde) ) Was administered orally.
  • mice After completion of dosing, fast for one day and the next day the mice are weighed and anesthetized, and blood is drawn from the heart (using a tube containing a small amount of 1.4% K 2 EDTA solution), followed by a Coulter counter (Coulter cooperation, USA). Red blood cells (RBC), white blood cells (WBC), and platelets (PLT) were measured.
  • RBC Red blood cells
  • WBC white blood cells
  • PHT platelets
  • peritoneal macrophage of mice was taken to measure immune cytokines, and the cells were placed in a 24-well plate at a concentration of 2.5 ⁇ 10 6/500 ⁇ l / well, and then cultured for 3 hours. Removed. Subsequently, after 48 hours of incubation, the concentration of IL-1ß and IFN- ⁇ in the culture medium was quantified using the ELISA kit, and the results are summarized in Table 3 below.
  • the erythrocyte (WBC) level was significantly reduced by 15% compared to the normal group when 5-FU alone.
  • erythrocyte levels were significantly increased by 12-15% compared to the 5-FU-treated group. Therefore, it could be confirmed that the administration of the functional food composition of the present invention recovered to 93-96% of the normal group.
  • the composition of the present invention is effective in restoring the composition of erythrocytes, leukocytes and platelets, which are the major constituents of blood, in the treatment of sequelae following administration of 5-FU, an anticancer drug, and the production of IL-1 and IFN- ⁇ , which are immune factors. It was found that the effect of recovering is excellent. In addition, the deterioration of the composition and function of blood by the administration of anticancer drugs is observed not only in chemotherapy but also in postoperative surgery and the elderly. Based on the above results, the health functional food composition according to the present invention is deteriorated after surgery or the elderly. It could be inferred that it could be effective for the deteriorated person.
  • Example 2> recovery evaluation of blood composition, antioxidant defense lowering in the human body
  • Intensive exercise stress causes anemia by increasing the rate of destruction rather than the rate of red blood cell production, and long-term, high-intensity training reduces leukocytes and lowers immunity.
  • exercise performance is improved by long-term, high-intensity training, but due to accumulated stress, hematological composition and function immediately after the training period tend to be very similar to those of patients. Therefore, the deterioration of blood composition and blood function, which is a common phenomenon in patients undergoing chemotherapy, postoperative patients and old age, can be evaluated under controlled conditions much better than in general patients.
  • the experiment was carried out in accordance with the one-month winter cell training period, and the intake group was to consume the composition 2 of Preparation Example 1 (9 capsules per day, 450 mg per capsule) for 4 weeks under the guidance of a coach.
  • a blood collection of 10 mm was performed using a disposable syringe.
  • Samples collected from the antecubital vein were divided into EDTA treatment tubes and serum separation tubes. Serum was obtained from the upper layer after centrifugation at 3000 rpm for 15 minutes, and the remaining blood components were analyzed in whole blood and plasma.
  • Red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb), and red blood cell volume (Hct) were measured in blood cells, and reduced glutathione (GSH) and catalase among blood antioxidant enzymes representing the antioxidant defenses of blood.
  • GSH glutathione
  • CAT malondialdehyde
  • MDA malondialdehyde
  • Reduced glutathione (GSH) concentration which is an indicator of blood antioxidant defense, was determined as the difference between total glutathione level and blood glutathione level.
  • 6% acetic acid and 10% sulfosalicylic acid were added to the blood, mixed, left for several minutes, and centrifuged at 5000 rpm for 5 minutes.
  • the supernatant obtained by centrifugation of the supernatant was diluted and mixed with a predetermined amount of nicotinamide adenine dinucleotide phosphate (NADPH) and DTNB (5,5'-dithio-bis-2-nitrobenzoicacid) at 35 ° C. It was left for a minute.
  • 50 ⁇ l of GR glutathion reductase, Sigma G3664
  • the total glutathione content was measured by comparing with the slope observed in the GSH reference curve.
  • Glutathione oxide (GSSG) concentration was measured as follows.
  • 6% acetic acid and 10% sulfosalicylic acid were added to the blood, mixed and allowed to stand for several minutes, followed by centrifugation at 5000 rpm for 5 minutes.
  • the supernatant obtained by recentrifugation was mixed with 2-VP (2-vinylpyridine, Sigma 132292) and shaken vigorously, and left at room temperature for 1 hour. This was diluted with a buffer, and a certain amount of NADPH and DTNB were mixed and left at 35 ° C for 5 minutes.
  • Catalase an indicator of blood antioxidant defense, was analyzed using Molecular Probes' catalase assay kit (A-22180).
  • HRP horseradish peroxidase
  • catalase reacts to reduce H 2 O 2 to water
  • HRP reacts with H 2 O 2 to produce a fluorescent substance called resorufin.
  • High catalase activity decreases the signal of resorufin.
  • the absorbance of Resorufin was measured at 570 nm and the concentration was calculated using the (catalase) reference curve. 1U is the enzyme amount was reduced to the H 2 O 2 in 1 ⁇ mol.
  • MDA malondialdehyde
  • TCA trichloroacetic acid
  • the red blood cell (RBC) level was significantly decreased in the group ingesting the composition of the present invention while the comparative group was slightly decreased.
  • WBC leukocytes
  • the control group showed a significant decrease while the intake group maintained the initial normal level.
  • Hb hemoglobin
  • Hct red blood cell volume
  • the placebo group showed a significant increase (P ⁇ 0.05), but the intake group did not show a significant increase.
  • the placebo group showed a significantly higher increase than the intake group (P ⁇ 0.05).
  • the increase rate of the group ingesting the composition of the present invention is lower than that of the placebo group. It is the result of suppressing lipid peroxidation by improving antioxidant function.
  • the health functional food composition of the present invention is expected to promote the recovery of health by restoring enzymes that can effectively remove various oxidative stress substances caused by anticancer therapy, chronic disease, senility, and exercise stress.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a composition for a functional food effective for restoring blood composition and function deteriorated by anticancer treatments, an operation, aging, or stress. The composition for a functional food comprises, in dry weight, 30 to 90 wt % of collagen, 3 to 60 wt % of linseed, 1 to 50 wt % of phlorotannin, 1 to 30 wt % of calcium, 0.1 to 3 wt % of iron, 0.01 to 0.5 wt % of vitamin E, and 0.01 to 0.1 wt % of vitamin B.

Description

혈액의 조성 및 기능 회복 효과를 갖는 기능성 식품용 조성물Functional food composition having blood composition and functional recovery effect
본 발명은 항암치료 및 수술 전후, 지병, 과도한 운동스트레스 혹은 노화로 인해 생기는 비정상적인 혈액 수치 및 기능을 회복시켜 건강을 회복하는데 효과적인 건강기능성 식품용 조성물에 관한 것이다. The present invention relates to a health functional food composition effective to restore health by restoring abnormal blood levels and functions caused by anti-cancer treatment and surgery, chronic disease, excessive exercise stress or aging.
본 발명은 2011년 01월 13일에 한국특허청에 제출된 한국특허출원 제10-2011-0003566 호의 출원일의 이익을 주장하며, 그 내용 전부는 본 명세서에 포함된다.The present invention claims the benefit of the filing date of the Korean Patent Application No. 10-2011-0003566 filed with the Korea Patent Office on January 13, 2011, the entire contents of which are incorporated herein.
수십 년 전부터 화학합성 또는 천연물 분리의 방법에 의해 많은 우수한 항암제 및 항암요법이 개발되어왔으며, 이러한 노력으로 인해 지난 수십 년간 암의 치료율이 획기적으로 향상되었다. 그러나 국소적인 암 병소의 제거에만 초점을 맞춘 기존 암 치료 법은 환자의 삶의 질 저하라는 문제를 야기하여 최근에는 화학요법 및 방사선 요법의 부작용으로 인한, 삶의 질 저하를 개선해야 할 필요성이 대두되고 있다. Many excellent anticancer and anticancer therapies have been developed by chemical synthesis or natural product separation methods for decades, and these efforts have dramatically improved the rate of cancer treatment over the last few decades. However, conventional cancer therapies, which focus only on the elimination of local cancer lesions, raise the problem of poor quality of life of patients. Recently, there is a need to improve the quality of life due to side effects of chemotherapy and radiation therapy. have.
화학요법제 5-플루오로우라실 (5-FU)은 1957년 최초로 합성되었으며 아직까지도 임상에서 널리 쓰이고 있다. 5-FU는 암세포 내에서 활성 뉴클레오티드로 전환되어 티미딜레이트 합성효소를 억제함으로써 세포의 DNA 합성을 저해하는 항암제로서 유방암, 대장암, 직장암, 위암, 췌장암, 식도암, 간암, 두경부암, 방광암에 임상적으로 광범위하게 쓰이며 피부암에도 국소적으로 사용되고 있다. 그러나 대표적인 부작용으로 조혈독성이 알려져 있으며, 그 밖에 심각한 위염, 식도염, 직장염, 설사 등의 소화기계 부작용의 발생빈도가 높고 피부의 색소과다증도 일으키는 것으로 알려져 있다. 또한 5-FU는 백혈구 수치의 감소 등의 조혈독성과 소장점막 슈크라제 활성 감소, 설사유발 등의 소화기 독성, 비장중량감소, 임파구감소 등의 면역독성을 유발한다는 것이 알려져 있다. The chemotherapeutic agent 5-fluorouracil (5-FU) was first synthesized in 1957 and is still widely used in clinical practice. 5-FU is an anticancer agent that inhibits thymidylate synthase by converting into active nucleotides in cancer cells and inhibits the synthesis of DNA of cells, and is clinically used for breast cancer, colon cancer, rectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, liver cancer, head and neck cancer and bladder cancer. It is widely used and is also used topically for skin cancer. However, hematopoietic toxicity is known as a representative side effect, and other side effects of gastrointestinal side effects such as severe gastritis, esophagitis, proctitis, and diarrhea are high and skin hyperpigmentation is known. In addition, 5-FU is known to cause hematopoietic toxicity, such as a decrease in white blood cell counts, decreased intestinal mucosal sucrase activity, digestive toxicity, such as diarrhea induction, spleen weight loss, and lymphocyte reduction.
그 외에도, 대표적인 화학요법제로서 아드리아마이신(adriamycin), 블레오마이신(bleomycin), 마이토마이신(mitomycin), 시스플라틴(cisplatin) 등이 있으며, 이들의 장기 투여시 DNA 합성과 세포분열의 억제 및 세포막 손상 등 DNA 손상으로 인한 가역적 또는 비가역적 부작용을 유발한다. In addition, typical chemotherapeutic agents include adriamycin, bleomycin, mitomycin, cisplatin, and their long-term administration of DNA synthesis, cell division inhibition, and cell membrane damage. And can cause reversible or irreversible side effects from DNA damage.
한편, 현재 전 세계적으로 수천만 명이 넘는 암환자들이 있으며 이들에게 적용되는 항암요법이 모두 심각한 부작용을 나타내고 있다. 암을 치료하기 위하여 사용되는 화학요법은 분열속도가 빠른 암세포를 죽이는 것이 목적이지만 이와 동시에 혈액세포 등 분열속도가 빠른 정상세포도 함께 파괴하게 된다. 따라서 화학요법에 의한 항암치료의 가장 대표적이며 공통적인 후유증으로서 혈액 세포의 파괴로 인한 혈액의 기능 장애를 들 수 있다. 예를 들어, 혈소판 감소증, 백혈구수 저하, 면역력 저하의 대표적인 현상으로 건강을 오히려 해치게 되고 삶의 질이 저하되는 경우가 많다. Meanwhile, there are currently tens of millions of cancer patients worldwide, and all of the chemotherapy applied to them have serious side effects. Chemotherapy, used to treat cancer, aims to kill cancer cells with rapid division, but at the same time destroys normal cells with rapid division such as blood cells. Therefore, the most representative and common sequelae of chemotherapy-based chemotherapy is a blood dysfunction due to the destruction of blood cells. For example, thrombocytopenia, reduced white blood cell count, and reduced immunity are typical phenomena that harm health and often deteriorate quality of life.
또한, 방사선치료시에 폭사되는 방사선 및 외과 수술 시행시에 전신 또는 국소마취제, 지혈제, 혈액응고 방지제 및 진통제의 병용투여에 따른 약물에 의한 활성산소(OH , NO2 등)의 발생과 대사과정의 일시적 불균형 및 출혈에 따른 일시적 빈혈 등 산화적 스트레스(oxidative stress)에 의한 체내의 활성산소 대량발생으로, 백혈구 수치의 저하, 혈소판감소, 면역력 저하, 혈액 내 항산화방어체계 기능 부진 등의 부작용을 가져올 수 있다.In addition, the generation of reactive oxygen (OH, NO2, etc.) and metabolic processes caused by drugs in combination with general or local anesthetics, hemostatic agents, anticoagulants, and analgesics during radiation and radiation surgery during radiation therapy Large amounts of free radicals in the body caused by oxidative stress, such as transient anemia due to imbalance and bleeding, can cause side effects such as decreased white blood cell counts, reduced platelets, decreased immunity and poor function of antioxidant defense system in the blood. .
따라서 항암요법 및 외과적 수술에 의한 후유증으로부터 건강을 효과적으로 회복하기 위해서는 혈액의 조성 회복과 면역기능 및 항산화방어력과 같은 혈액 기능의 효과적인 회복이 중요하다. 또한 지병을 앓고 난 사람들이나 노약자의 경우, 지속적이고 과도한 운동을 하는 경우에도 혈액의 조성이 불완전 하며, 면역기능 이나 항산화 방어기능이 저하되어 있으므로, 혈액의 조성과 기능의 회복은 건강 회복에 있어서 중요하다. Therefore, in order to effectively recover the health from the sequelae caused by chemotherapy and surgical operation, it is important to restore the composition of blood and effective recovery of blood functions such as immune function and antioxidant defense. In addition, people suffering from chronic illnesses or the elderly are incomplete in the composition of blood even after constant and excessive exercise, and the immune function and antioxidant defense function are deteriorated. Therefore, the recovery of blood composition and function is important for the recovery of health. Do.
일반적인 회복식은 필수영양소나 항산화제의 풍부한 공급에 그치거나, 명확한 화학적 성분을 알 수 없는 식품 원재료로 구성되어 있으며(대한민국 등록특허 제0722698호, 제0591539호, 제0355012호), 항암치료부작용억제용 한약재 조성물(대한민국 등록특허 제0519456호)은 백혈구, 적혈구, 혈소판 및 면역력을 회복시키는 경향을 나타낸다고 공개하였으나, 건강회복의 중요한 지표인 항산화 방어력의 회복에 대한 효과가 나타나 있지 않으며, 한약재 복합조성으로서 성분의 명확한 표준화가 어렵고 식품으로서의 일반적 적용이 어려운 한계가 있다. The general recovery formula consists only of abundant supply of essential nutrients or antioxidants, or consists of food ingredients whose chemical composition is unknown (Korean Patent Nos. 0722698, 0591539, and 0355012). Herbal medicine composition (Korean Patent No. 0519456) has been shown to show a tendency to restore white blood cells, red blood cells, platelets and immunity, but it does not show an effect on the recovery of antioxidant defenses, which is an important indicator of health recovery, and as an herbal medicine composite composition There is a limit to the difficulty of clear standardization and the general application as a food.
이에 본 발명자들은 혈액의 조성 및 기능의 회복을 효과적으로 달성하는 식품 조성을 개발하기 위하여, 영양학적, 한의학적 및 생화학적인 관점에서의 다양한 성분들의 특성에 대한 고찰을 한 결과, 혈액의 재료가 되는 성분, 혈액의 생성을 촉진하는 성분, 혈액의 염증인자를 제거하는 성분 및 혈액의 항산화 기능을 촉진하는 성분의 특정한 조합 및 이에 대한 효과를 평가함으로써 상기의 한계를 극복할 수 있음을 알게 되어 본 발명을 완성하였다.Accordingly, the present inventors have studied the characteristics of various components from a nutritional, oriental medical and biochemical point of view in order to develop a food composition that effectively achieves the recovery of blood composition and function, and thus, the components of the blood, blood The present invention has been completed by evaluating specific combinations of components that promote the production of oxidants, components that remove inflammatory factors in the blood, and components that promote the antioxidant function of the blood, and effects thereof, thereby completing the present invention. .
상기와 같은 한계를 극복하기 위한 본 발명의 목적은, 콜라겐 30~90 중량%, 아마씨 3~60 중량%, 플로로탄닌 1~50 중량%, 칼슘 1~30 중량%, 철 0.1~3 중량%, 비타민 E 0.01~0.5 중량% 및 비타민 B 0.01~0.1 중량%를 포함하는 건강기능성 식품용 조성물을 제공하는 것이다.An object of the present invention for overcoming the above limitations, collagen 30 to 90% by weight, flaxseed 3 to 60% by weight, fluorotannin 1 to 50% by weight, calcium 1 to 30% by weight, iron 0.1 to 3% by weight To provide a health functional food composition comprising 0.01 to 0.5% by weight of vitamin E and 0.01 to 0.1% by weight of vitamin B.
또한, 이러한 건강 기능성 식품용 조성물 100 중량부에 대하여 부형성분 1 내지 1000 중량부를 포함하는 것을 특징으로 하는 건강기능성 식품을 제공하는 것이다.The present invention also provides a health functional food comprising 1 to 1000 parts by weight of an excipient component with respect to 100 parts by weight of such a health functional food composition.
본 발명은 콜라겐 30~90 중량%, 아마씨 3~60 중량%, 플로로탄닌 1~50 중량%, 칼슘 1~30 중량%, 철분 0.1~3 중량%, 비타민 E 0.01~0.5 중량% 및 비타민 B 0.01~ 0.1 중량%를 포함하는 건강기능성 식품용 조성물을 제공한다. The present invention is 30 to 90% by weight of collagen, 3 to 60% by weight flaxseed, 1 to 50% by weight of phlorotannin, 1 to 30% by weight of calcium, 0.1 to 3% by weight of iron, 0.01 to 0.5% by weight of vitamin E and vitamin B It provides a health functional food composition comprising 0.01 to 0.1% by weight.
또한, 본 발명은 항암치료 과정 및 전후, 수술 전후, 지병, 과도한 운동, 과도한 정신적 스트레스 또는 노환으로 인한 체력저하의 경우에 사용할 수 있는 건강기능성 식품용 조성물을 제공한다.In addition, the present invention provides a health functional food composition that can be used in the case of anti-cancer treatment process before and after, before and after surgery, limb disease, excessive exercise, excessive mental stress or physical degradation due to aging.
또한, 본 발명은 이러한 건강기능성 식품용 조성물을 편리하게 섭취할 수 있도록 정제, 캡슐제, 환제, 과립제, 액상제제, 음료, 유동식, 죽, 빵, 바 및 쿠키의 형태로 제공한다. In addition, the present invention provides in the form of tablets, capsules, pills, granules, liquid formulations, beverages, liquid, porridge, bread, bars and cookies so as to conveniently consume such a health food composition.
또한, 본 발명은 상기와 같은 건강기능성 식품용 조성물 100 중량부에 대하여 부형성분 1 내지 1000 중량부를 포함하는 건강기능성 식품을 제공한다.The present invention also provides a health functional food comprising 1 to 1000 parts by weight of the excipient component with respect to 100 parts by weight of the composition for health functional food as described above.
본 발명의 건강기능성 식품용 조성물을 섭취할 경우, 약물, 스트레스 상황 등으로 인한 혈액의 조성이상 및 기능부전을 개선하여 혈액의 조성이나 항산화기능을 정상치로 회복시킬 수 있다. Ingestion of the health functional food composition of the present invention can improve blood composition abnormality and dysfunction due to drugs, stress conditions, etc., can restore blood composition or antioxidant function to a normal value.
이하, 본 발명을 구체적으로 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 콜라겐 30~90 중량%, 아마씨 3~60 중량%, 플로로탄닌 1~50 중량%, 칼슘 1~30 중량%, 철분 0.1~3 중량%, 비타민 E 0.01~ 0.5 중량% 및 비타민 B 0.01~ 0.1 중량%를 포함하는 건강기능성 식품용 조성물을 제공한다.The present invention is 30 to 90% by weight of collagen, 3 to 60% by weight flaxseed, 1 to 50% by weight of phlorotannin, 1 to 30% by weight of calcium, 0.1 to 3% by weight of iron, 0.01 to 0.5% by weight of vitamin E and vitamin B It provides a health functional food composition comprising 0.01 to 0.1% by weight.
콜라겐은 동물의 뼈·연골 및 물고기의 비늘 등을 구성하는 경단백질로, 섬유상 고체로 존재하고, 물에 녹지 않지만 끓이면 젤라틴이 되어 용해된다. 구성 아미노산으로서 프롤린·옥시프롤린·글리신 등을 포함한다. 혈액의 생성에 필요한 기초재료로서 풍부한 단백질 공급원이며, 혈액 내 알부민과 면역글로불린 생성에 도움을 준다. 본 발명에 있어 콜라겐이 30 중량% 미만이나 90 중량%를 초과하도록 포함되면 효과가 반감되거나 경제적으로 적합하지 못하다.Collagen is a light protein constituting animal bones, cartilage, fish scales and the like. It is present as a fibrous solid and insoluble in water but becomes gelatin when dissolved. Proline amino acid includes proline, oxyproline, glycine and the like. It is a rich source of protein for the production of blood and helps to produce albumin and immunoglobulin in the blood. In the present invention, when the collagen is included to less than 30% by weight or more than 90% by weight, the effect is halved or economically unsuitable.
본 발명에 사용되는 콜라겐은 생선류 또는 육류에서 유래하는 것이나, 이에 한정되지는 않는다.Collagen used in the present invention is derived from fish or meat, but is not limited thereto.
아마는 쌍떡잎식물 쥐손이풀목 아마과의 한해살이풀로서 유럽과 아르헨티나 등에 분포한다. 아마의 씨에는 식물성 에스트로겐인 리그난과 식물성 단백질이 풍부하여 알부민과 글로불린을 만드는데 도움을 주므로 인체 면역성을 높이는데 좋다. 본 발명에 있어 아마씨가 3 중량% 미만으로 포함되면 효과가 떨어지며 60 중량%를 초과하면 원하는 제형을 만들기 어렵다.Flax is a perennial plant of the dicotyledonous rat, Ratus Arachnid, distributed in Europe and Argentina. Flax seeds are rich in phytoestrogens, lignans and plant proteins, which help to make albumin and globulin, which is good for boosting human immunity. In the present invention, when the flaxseed is included in less than 3% by weight is less effective, if it exceeds 60% by weight it is difficult to make the desired formulation.
본 발명에 사용되는 아마씨는 가루나 액체로 사용될 수 있으나 이에 한정되지는 않는다.Flaxseed used in the present invention may be used as a powder or a liquid, but is not limited thereto.
플로로탄닌은 갈조류 등에 존재하는 탄닌의 일종으로서 수용성과 지용성의 중간 영역의 강력한 항산화제이다. 최근 혈관의 기능 복원이나 염증인자 제거에 대한 많은 연구 결과가 발표되고 있다. Phlorotannin is a kind of tannin that exists in brown algae and the like and is a powerful antioxidant in the middle region of water-soluble and fat-soluble. Recently, many studies on the restoration of blood vessel function and the removal of inflammatory factors have been published.
본 발명에 사용되는 플로로탄닌은 바람직하게는 에콜(eckol), 디에콜(dieckol), 6,6'-비에콜(6,6'-bieckol), 8,8'-비에콜(8,8'-bieckol), 2-O-(2,4,6-트리하이드록시페닐)-6,6'-비에콜(2-O-(2,4,6-trihydroxyphenyl)-6,6'-bieckol), 플로로퓨코퓨로에콜(phlorofucofuroeckol), 퓨코퓨로에콜(fucofuroeckol), 2-플로로에콜(2-phloroeckol), 7-플로로에콜(7-phloroeckol), 트리플로레톨(triphlorethol), 플로로탄닌 A(phlorotannin A)으로 구성되는 그룹에서 선택되는 1종 또는 2종 이상의 혼합물이나, 이에 한정되지는 않는다. The phlorotannin used in the present invention is preferably ecol, dieckol, 6,6'-bieckol, 8,8'-bieckol (8,8). '-bieckol), 2-O- (2,4,6-trihydroxyphenyl) -6,6'-biechol (2-O- (2,4,6-trihydroxyphenyl) -6,6'-bieckol ), Phloofucofuroeckol, fucofuroeckol, 2-phloroeckol, 7-phloroeckol, triplehlorethol, floh One or two or more mixtures selected from the group consisting of rotannin A (phlorotannin A), but is not limited thereto.
본 발명에 있어 플로로탄닌이 1 중량% 미만으로 포함되면 효과가 떨어지고 50 중량%를 초과하면 경제적으로 적합하지 못하다.In the present invention, when the phlorotannin is included in less than 1% by weight, the effect is inferior.
칼슘은 주기율표상 원자번호 19번에 해당하는 알칼리토금속으로서, 혈액응고, 근육 수축 등 신체의 기본적인 활동 조절에 중요한 무기질이다. 식생활에서 가장 결핍되기 쉬운 영양소이며, 1일 섭취 권장량은 성인기준으로 700 mg에 달한다. Calcium is an alkaline earth metal corresponding to atomic number 19 on the periodic table, and is an important mineral for regulating basic activities of the body such as blood coagulation and muscle contraction. It is the most nutrient deficient in the diet, and the recommended daily intake reaches 700 mg in adults.
본 발명에 있어 칼슘이 1 중량% 미만으로 포함되면 효과가 떨어지고 30 중량%를 초과하면 제형을 만들기 어렵다.In the present invention, when the calcium is included in less than 1% by weight is less effective, if it exceeds 30% by weight it is difficult to make a formulation.
철은 주기율표상 원자번호 26번에 해당하는 금속으로서 산소의 운반과 세포 호흡의 생리 과정에서 꼭 필요한 무기질이며 적혈구 생성에 필수적이다. 성인여성의 경우 1일 섭취 권장량은 12~15mg이다. Iron is a metal corresponding to atomic number 26 in the periodic table, which is an essential mineral in the physiological process of oxygen transport and cellular respiration. It is essential for red blood cell production. For adult women, the recommended daily intake is 12-15 mg.
본 발명에 있어 철이 0.1 중량% 미만으로 포함되면 효과가 감소하고 3 중량%를 초과하면 원하는 제형을 만들기 어렵거나 제형의 색상, 유효기간에 좋지 않은 영향을 미친다.In the present invention, when the iron is included in less than 0.1% by weight, the effect is reduced and when the content exceeds 3% by weight it is difficult to make the desired formulation or adversely affect the color, shelf life of the formulation.
비타민 E는 토코페롤이라고 불리우며, 지용성 비타민으로서 항산화 역할을 한다. Vitamin E is called tocopherol and acts as an antioxidant as a fat-soluble vitamin.
본 발명에 있어 비타민 E가 0.01 중량% 미만으로 포함되면 효과가 감소하고 0.5 중량%를 초과하면 독성의 염려가 있다.In the present invention, when vitamin E is included in less than 0.01% by weight, the effect is reduced, and when it exceeds 0.5% by weight, there is concern of toxicity.
비타민 B는 여러 아형이 존재하고 면역체계 강화 및 신진대사 촉진작용이 있다. 본 발명에 있어 비타민 B가 0.01 중량% 미만으로 포함되면 효과가 감소하고 0.1 중량%를 초과하면 제형의 유효기간에 좋지 않은 영향을 미친다.Vitamin B is present in several subtypes, immune system and metabolism promoting action. In the present invention, if the vitamin B is included in less than 0.01% by weight, the effect is reduced, while exceeding 0.1% by weight adversely affects the shelf life of the formulation.
또한 본 발명에 따른 조성물은 콜라겐 30~90 중량%, 아마씨 3~60 중량%, 플로로탄닌 1~50 중량%, 칼슘 1~30 중량%, 철 0.1~3 중량%, 비타민 E 0.01~0.5 중량% 및 비타민 B 0.01~0.1 중량%를 포함하는 건강기능성 식품용 조성물에, 레시틴 1~ 10 중량%, 리그난 0.005~3 중량%, 및 구리 0.01~ 0.2 중량%를 더 포함할 수 있다.In addition, the composition according to the present invention is 30 to 90% by weight of collagen, 3 to 60% by weight of flaxseed, 1 to 50% by weight of phlorotannin, 1 to 30% by weight of calcium, 0.1 to 3% by weight of iron, 0.01 to 0.5% by weight of vitamin E. In a dietary supplement composition comprising% and 0.01 to 0.1% by weight of vitamin B, 1 to 10% by weight of lecithin, 0.005 to 3% by weight of lignan, and 0.01 to 0.2% by weight of copper may be further included.
레시틴은 글리세린 인산을 포함하고 있는 인지질의 하나이며 생체막을 구성하는 주요 성분으로, 난황·콩기름·간·뇌 등에 많이 있다.Lecithin is one of the phospholipids containing glycerin phosphoric acid and is a major component of the biofilm, which is found in egg yolk, soybean oil, liver and brain.
리그난은 n-페닐프로페인이 n-프로필 곁사슬의 ß자리에서 2분자가 결합한 천연물의 총칭으로 항산화제인 동시에 식물성 에스트로겐에 해당한다.Lignan is a generic term for natural products in which n-phenylpropane is a two-molecule bond in the ß site of the n-propyl side chain. It is also an antioxidant and phytoestrogens.
구리는 주기율표상 원자번호 29번에 해당하는 금속으로서 철분의 이용과 적혈구 합성에 도움을 준다. 성인의 경우 1일 섭취 권장량은 1.5~3 mg이다.Copper is a metal with atomic number 29 in the periodic table that aids in the use of iron and in the synthesis of red blood cells. For adults, the recommended daily intake is 1.5 to 3 mg.
본 발명의 한 구현예에 따르면, 마우스에 항암제인 5-FU를 투여한 후 부작용 억제 효과를 평가한 결과, 본 발명에 따른 조성물을 투여한 경우 유의하게 혈소판, 백혈구, 적혈구 수치를 상승시켰고, 면역력 판단의 기준인 여러 사이토카인의 수치도 상승하였다. According to one embodiment of the present invention, when the anti-cancer drug 5-FU was administered to the mouse, the side effect inhibitory effect was evaluated, and the administration of the composition according to the present invention significantly increased platelet, leukocyte, and red blood cell levels, and immunity. The levels of several cytokines, the criteria for judgment, also rose.
또한, 본 발명의 다른 한 구현예에 따르면, 대학에 재학 중인 남자 싸이클 운동선수 40명을 대상으로 고강도 동계 전지훈련 전후에 혈액 조성 회복 정도를 평가한 결과, 본 발명에 따른 조성물을 투여한 경우 유의하게 백혈구, 적혈구, 혈색소 및 적혈구용적률 수치를 상승시켰다. In addition, according to another embodiment of the present invention, as a result of evaluating the degree of blood composition recovery before and after high-intensity winter cell training for 40 male cycle athletes in college, the administration of the composition according to the present invention Leukocytes, red blood cells, hemoglobin and red blood cell volume levels were elevated.
따라서 본 발명에 따른 건강기능성 식품용 조성물은 혈액의 조성을 정상치로 회복시키는 것을 알 수가 있다.Therefore, the health functional food composition according to the present invention can be seen to restore the blood composition to the normal value.
또한, 상기 대학에 재학 중인 남자 싸이클 운동선수 40명을 대상으로 고강도 동계 전지훈련 전후에 본 발명에 따른 건강기능성 식품용 조성물이 혈액의 항산화 기능에 미치는 효과를 판단하기 위하여, 혈액 내 대표적 항산화 물질인 글루타치온과 카탈라아제 및 혈액의 산화 스트레스 정도를 나타내는 지질과산화 물질인 malondialdehyde(MDA)를 각각 측정한 결과, 플라시보군에 비하여 글루타치온과 카탈라아제의 수치는 상승하는 반면, MDA 수치는 감소하는 것을 확인할 수 있었다. In addition, in order to determine the effect of the health functional food composition according to the present invention on the antioxidant function of blood before and after high intensity winter cell training for 40 male cycle athletes who are attending the university, the representative antioxidant substance in the blood Glutathione, catalase and malondialdehyde (MDA), a lipid peroxidation agent that indicates the degree of oxidative stress in the blood, were measured, respectively. As compared with the placebo group, the levels of glutathione and catalase were increased, but the MDA levels were decreased.
따라서 본 발명에 따른 건강기능성 식품용 조성물은 혈액의 항산화기능을 정상치로 회복시키는 것을 알 수가 있다.Therefore, it can be seen that the health functional food composition according to the present invention restores the antioxidant function of blood to a normal value.
본 발명에 따른 건강기능성 식품용 조성물은 항암치료 과정 및 전후, 수술 전후, 지병, 과도한 운동, 과도한 정신적 스트레스 또는 노환으로 인한 체력저하의 경우에 사용될 수 있으나, 이에 한정되지는 않는다.Health functional food composition according to the present invention can be used in the case of anti-cancer treatment process before and after, before and after surgery, chronic disease, excessive exercise, excessive mental stress or physical strength decline due to aging, but is not limited thereto.
본 발명에 따른 건강기능성 식품용 조성물은 정제, 캡슐제, 환제, 과립제 액상제제, 음료, 유동식, 죽, 빵, 바 및 쿠키의 형태로 제조하여 편의성을 도모할 수 있으나, 이에 한정되지는 않는다.The health functional food composition according to the present invention may be prepared in the form of tablets, capsules, pills, liquid granules, beverages, liquid, porridge, bread, bars, and cookies for convenience, but is not limited thereto.
또한, 본 발명은 상기 건강기능성 식품용 조성물 100 중량부에 대하여 부형성분 1~1000 중량부를 포함하는 것을 특징으로 하는 건강기능성 식품을 제공한다.In addition, the present invention provides a health functional food comprising 1 to 1000 parts by weight of excipient components based on 100 parts by weight of the composition for health functional food.
상기 부형성분은 찹쌀, 맵쌀, 밀가루, 꿀, 결정 셀룰로오스, 이산화규소, 결정과당, 무수구연산, 이눌린, 비타민C, 참기름, 간장, 버터, 이스트, 소금, 설탕, 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바 납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 덱스트로스, 소르비톨, 탈크 등이 사용될 수 있으나 이에 한정되지는 않는다. 상기 부형성분은 상기 조성물에 대해 1~1000 중량부 포함되는 것이 바람직하나, 이에 한정되는 것은 아니다.The excipients are glutinous rice, spicy rice, wheat flour, honey, crystalline cellulose, silicon dioxide, fructose, anhydrous citric acid, inulin, vitamin C, sesame oil, soy sauce, butter, yeast, salt, sugar, starch, gelatinized starch, microcrystalline cellulose, Lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, sodium starch glycolate, carnauba lead, Synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, dextrose, sorbitol, talc and the like may be used, but is not limited thereto. The excipient component is preferably included 1 to 1000 parts by weight based on the composition, but is not limited thereto.
이하, 본 발명을 실시예에 의해 구체적으로 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, an Example demonstrates this invention concretely. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
<제조예 1> 조성물의 제조Preparation Example 1 Preparation of Composition
각 성분의 함량을 다양하게 변화시킨 조성물을 제조하였다.A composition was prepared in which the content of each component was varied.
표 1
성분(건조중량%) 조성물1 조성물2 조성물3 조성물4 조성물5 조성물6 조성물7 조성물8 조성물9 조성물10
콜라겐 40 60 80 65 60 60 50 50 50 60
아마씨 가루 40 20 5 16 18 18 24 12 5 18
플로로탄닌 5 5 5 28 25 7 10 20 35 7
칼슘 10 10 5 14 12 14 12 12 4 14
철 1.5 1.5 1.5 0.8 0.5 0.75 0.7 0.7 0.2 0.75
비타민E 0.35 0.2 0.2 0.275 0.25 0.1 0.2 0.05 0.3 0.1
비타민B 0.075 0.05 0.05 0.04 0.015 0.075 0.05 0.2 0.05 0.15
레시틴 3 3 3 1 5 0 3 5 5 0
리그난 0 0.2 0.2 0.01 1.6 0.075 0.025 0 0.4 0
구리 0.075 0.05 0.05 0.075 0.135 0 0.025 0.05 0.05 0
합계 100 100 100 100 100 100 100 100 100 100
Table 1
Ingredients (dry weight%) Composition 1 Composition 2 Composition 3 Composition 4 Composition 5 Composition 6 Composition 7 Composition 8 Composition 9 Composition 10
Collagen 40 60 80 65 60 60 50 50 50 60
Flaxseed powder 40 20 5 16 18 18 24 12 5 18
Phlorotannin 5 5 5 28 25 7 10 20 35 7
calcium 10 10 5 14 12 14 12 12 4 14
iron 1.5 1.5 1.5 0.8 0.5 0.75 0.7 0.7 0.2 0.75
Vitamin E 0.35 0.2 0.2 0.275 0.25 0.1 0.2 0.05 0.3 0.1
Vitamin B 0.075 0.05 0.05 0.04 0.015 0.075 0.05 0.2 0.05 0.15
lecithin 3 3 3 One 5 0 3 5 5 0
Lignan 0 0.2 0.2 0.01 1.6 0.075 0.025 0 0.4 0
Copper 0.075 0.05 0.05 0.075 0.135 0 0.025 0.05 0.05 0
Sum 100 100 100 100 100 100 100 100 100 100
표 2
성분(건조중량%) 비교예1 비교예2 비교예3 비교예4 비교예5 비교예6 비교예7
콜라겐 67 75 0 70 65.8 65.275 65.04
아마씨 가루 16.8 0 42 20 16 16 16
플로로탄닌 0 9.8 42.8 7.8 2.8 2.8 2.8
칼슘 14 14 14 0 14 14 14
철 0.8 0.8 0.8 0.8 0 0.8 0.8
비타민 E 0.275 0.275 0.275 0.275 0.275 0 0.275
비타민 B 0.04 0.04 0.04 0.04 0.04 0.04 0
레시틴 1 0 0 1 1 1 1
리그난 0.01 0.01 0.01 0.01 0.01 0.01 0.01
구리 0.075 0.075 0.075 0.075 0.075 0.075 0.075
합계 100 100 100 100 100 100 100
TABLE 2
Ingredients (dry weight%) Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Comparative Example 7
Collagen 67 75 0 70 65.8 65.275 65.04
Flaxseed powder 16.8 0 42 20 16 16 16
Phlorotannin 0 9.8 42.8 7.8 2.8 2.8 2.8
calcium 14 14 14 0 14 14 14
iron 0.8 0.8 0.8 0.8 0 0.8 0.8
Vitamin E 0.275 0.275 0.275 0.275 0.275 0 0.275
Vitamin B 0.04 0.04 0.04 0.04 0.04 0.04 0
lecithin One 0 0 One One One One
Lignan 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Copper 0.075 0.075 0.075 0.075 0.075 0.075 0.075
Sum 100 100 100 100 100 100 100
<제조예 2> 제형예Preparation Example 2 Formulation Example
본 발명에 따른 건강기능성 식품용 조성물은 하기와 같은 방법을 통해 제형화하여 섭취할 수 있다.The health functional food composition according to the present invention can be formulated and ingested through the following method.
1. 환의 제조 및 섭취 방법1. Preparation and consumption of pill
찹쌀, 밀가루, 꿀, 물을 1:1:0.5:3의 중량비로 혼합하고, 끓인 후 상온으로 식혀 풀을 만든다. 만들어진 풀:조성물1을 1:9의 중량비로 반죽하여 각각 2 g의 환으로 제조한다. 1일 2개의 환 (4 g)을 식후에 씹어서 섭취한다.Glutinous rice, flour, honey, water is mixed in a weight ratio of 1: 1: 0.5: 3, boiled and cooled to room temperature to make a paste. The resulting paste: composition 1 is kneaded in a weight ratio of 1: 9 to prepare 2 g of each ring. Two pills (4 g) per day are eaten after chewing.
2. 정제의 제조 및 섭취 방법2. Preparation and Intake Method of Tablets
조성물2, 유당, 결정셀룰로오스, 이산화규소 및 스테아린산마그네슘을 35:25:37:1:1의 중량비로 혼합한 후, 타정기를 사용하여 정제 (600 mg)를 제조한다. 1일 6-10정을 식후에 섭취한다.Composition 2, lactose, crystalline cellulose, silicon dioxide and magnesium stearate are mixed in a weight ratio of 35: 25: 37: 1: 1 and then tableted (600 mg) is prepared using a tablet press. Take 6-10 tablets daily.
3. 음료의 제조 및 섭취 방법3. Preparation and Intake of Beverages
조성물4, 결정과당, 무수구연산, 이눌린, 비타민C 및 물을 2:8:1:8:0.2:160의 중량비로 혼합한 후, 5분간 교반하면서 끓인 후 냉각시킨다. 1일 180 mL의 음료를 2회 섭취한다. Composition 4, fructose, citric anhydride, inulin, vitamin C and water are mixed in a weight ratio of 2: 8: 1: 8: 0.2: 160, and then boiled with stirring for 5 minutes and then cooled. Take 180 mL of drink twice daily.
4. 죽의 제조 및 섭취 방법4. How to make and intake porridge
찹쌀과 맵쌀을 1:1로 하여 죽을 끓인 후, 뜨거운 상태의 약 200 g의 죽에 조성물6 2 g, 참기름 0.5 g, 간장 0.5 g을 혼합하여 죽을 제조한다. 1일 2회 식사 대용으로 섭취한다. After boiled porridge with glutinous rice and spicy rice in a 1: 1 ratio, 2 g of composition 6, 0.5 g of sesame oil, and 0.5 g of soy sauce are mixed with about 200 g of hot porridge to prepare porridge. Take in place of meals twice daily.
5. 빵의 제조 및 섭취 방법5. How to make and consume bread
밀가루 250 g, 버터 30 g, 이스트 6.5 g, 소금 5 g, 설탕 37.5 g, 물 130 g, 조성물9 20 g을 혼합한 후 반죽을 하여 37℃에서 1차 발효를 시킨 후, 30 g씩 분할하여 팬에 담아 나열하고 다시 2차 발효 후 부풀어 오른 위에 계란을 풀어 발라준다. 오븐 온도 180℃에서 15분 정도 굽는다. 1일 2, 3회 식사대용 혹은 간식으로 섭취한다.250 g of wheat flour, 30 g of butter, 6.5 g of yeast, 5 g of salt, 37.5 g of sugar, 130 g of water, 20 g of composition 9 were mixed and kneaded firstly at 37 ° C., and then divided into 30 g each. List them in a pan and, after the second fermentation, loosen the eggs on the swelled top and apply them. Bake at oven temperature 180 ° C. for 15 minutes. Take it as a meal replacement or snack 2 or 3 times a day.
6. 캡슐의 제조 및 섭취 방법6. Preparation and intake method of capsule
조성물2 및 스테아린산마그네슘을 99.8:0.2의 중량비로 혼합한 후, 경질 캡슐(젤라틴 성분)에 각 450 mg씩 충진하여, 1일 3-9 캡슐을 섭취한다. After mixing Composition 2 and magnesium stearate in a weight ratio of 99.8: 0.2, the hard capsule (gelatin component) is filled with 450 mg of each, and 3-9 capsules are taken daily.
7. 유동식의 제조 및 섭취 방법7. Preparation of Formulation and Intake Method
현미가루, 미역가루, 당근즙, 사과즙, 소금, 조성물10 및 물을 5:1:10:10:0.1:2:200의 중량비로 혼합하여 끓인 후 상온으로 식힌다. 튜브가 달린 유동식 플라스틱 주머니에 담아 환자의 상태에 따라 섭취 시킨다. Brown rice powder, brown seaweed powder, carrot juice, apple juice, salt, composition 10 and water are mixed at a weight ratio of 5: 1: 10: 10: 0.1: 2: 200, boiled and cooled to room temperature. Put it in a plastic bag with a tube and take it according to the patient's condition.
8. 쿠키의 제조 및 섭취 방법8. How to make and consume cookies
버터 80 g을 녹인 후 설탕 100 g 및 계란 1개 (50 g)을 넣고 휘저으며, 밀가루(180 g), 베이킹파우다(작은 숫가락 1/2정도 또는 약 2.5 mL), 베이킹소다(작은 숫가락 1/2정도 또는 약 2.5 mL)를 채를 통과시켜 첨가하고, 이어서 조성물3 12 g을 채를 이용하여 첨가한 후 잘 혼합한다. 오븐 온도 180℃에서 15분 정도 굽는다. 1일 2, 3회 간식으로 섭취한다. Melt 80 g of butter and stir with 100 g of sugar and 1 egg (50 g), flour (180 g), baking powder (about 1/2 small spoon or about 2.5 mL), baking soda (small spoon) 1/2 or about 2.5 mL) is added through a shaker, and then 12 g of composition 3 is added using a shaker and mixed well. Bake at oven temperature 180 ° C. for 15 minutes. Take it as a snack two or three times a day.
9. 바(bar)의 제조 및 섭취 방법9. How to prepare and consume bar
버터 40 g을 녹인 후 참기름 40 g, 설탕 100 g 및 젤라틴 100 g을 넣고 휘저으며, 밀가루 180 g, 베이킹파우다(작은 숫가락 1/2정도 또는 약 2.5 mL), 베이킹소다(작은 숫가락 1/2정도 또는 약 2.5 mL)를 채를 통과시켜 첨가한 후, 호두 30 g을 첨가하고, 이어서 조성물5 12g을 채를 이용하여 첨가한 후 잘 혼합한다. 완성된 반죽을 폭 3 cm, 길이 9 cm, 깊이 2 cm의 은박지 틀에 70% 정도의 부피로 채워 넣고, 180℃의 온도로 오븐에서 15분 정도 굽는다. 1일 2, 3개를 간식으로 섭취한다. Melt 40 g of butter, stir in 40 g of sesame oil, 100 g of sugar and 100 g of gelatin, 180 g of flour, baking powder (about 1/2 small spoon or about 2.5 mL), baking soda (small spoon 1 / 2 or about 2.5 mL) is added through a shaker, then 30 g of walnuts are added, followed by 12 g of composition 5 with a shaker and mixed well. The finished dough is filled with a volume of about 70% in a silver foil frame 3 cm wide, 9 cm long, and 2 cm deep, and baked in an oven at 180 ° C. for 15 minutes. Take two or three snacks a day.
<실시예 1> 마우스 모델을 이용한 혈액의 조성 및 기능 회복 실험 Example 1 Blood Composition and Function Recovery Experiments Using a Mouse Model
임상적으로 가장 널리 쓰이고 있는 항암제 중 하나인 5-FU (5-fluorouracil: 5-FU)의 부작용 억제 효능을 평가하였다. C57BL/6 마우스를 군당 10 마리씩으로 나누고 오른쪽 옆구리의 털을 깍은 후, B16-BL6 멜라노마 세포를 마우스 당 5x105~1x106 cell씩 0.1 ㎖의 부피로 피하에 주사하였다. 7일 후 뚜렷한 종양이 피부에 형성된 것을 확인한 후, 각각의 마우스에 5-FU를 1회씩 복강 투여한 후 제조예 1의 조성물4를 일일 1회 7일간 70 mg/kg체중의 양으로 존데(sonde)를 사용하여 경구 투여하였다. 투여를 완료한 후, 하루 동안 절식시키고 다음날 마우스를, 무게를 재고 마취시킨 후 심장으로부터 채혈(1.4% K2EDTA용액이 소량 담긴 튜브 사용) 한 후, Coulter counter(Coulter cooperation, USA)를 사용하여 적혈구(RBC), 백혈구(WBC), 혈소판(PLT)을 측정하였다. 또한, 면역 사이토카인을 측정하기 위하여 마우스의 복강 대식세포(peritoneal macrophage)를 취하여, 24-well plate에 2.5X106/500 ㎕/well의 농도로 넣은 후, 3시간 배양 후, 비접착성 세포를 제거하였다. 이어서 48시간 배양한 후, 세포 배양 상등액을 ELISA kit를 이용하여 배양액의 IL-1ß및 IFN-γ의 농도를 정량하여 그 결과를 하기 표 3에 정리하였다.One of the most widely used anticancer drugs, 5-FU (5-fluorouracil) was evaluated. After dividing the C57BL / 6 mice into groups of 10 mice and shaving the right flank, B16-BL6 melanoma cells were injected subcutaneously in a volume of 0.1 ml of 5 × 10 5 to 1 × 10 6 cells per mouse. After 7 days, it was confirmed that a distinct tumor was formed on the skin, and each mouse was intraperitoneally administered once with 5-FU, and then the composition 4 of Preparation Example 1 was once daily for 7 days at 70 mg / kg body weight (sonde) ) Was administered orally. After completion of dosing, fast for one day and the next day the mice are weighed and anesthetized, and blood is drawn from the heart (using a tube containing a small amount of 1.4% K 2 EDTA solution), followed by a Coulter counter (Coulter cooperation, USA). Red blood cells (RBC), white blood cells (WBC), and platelets (PLT) were measured. In addition, peritoneal macrophage of mice was taken to measure immune cytokines, and the cells were placed in a 24-well plate at a concentration of 2.5 × 10 6/500 μl / well, and then cultured for 3 hours. Removed. Subsequently, after 48 hours of incubation, the concentration of IL-1ß and IFN-γ in the culture medium was quantified using the ELISA kit, and the results are summarized in Table 3 below.
표 3
Group PLT(106/㎕) WBC(103/㎕) RBC(106/㎕) IL-1ß(pg/mL) IFN-γ(pg/mL)
정상군 1.24±0.25 3.52±0.61 9.03±0.43 7.25±0.77 27.32±2.32
음성대조군(5-FU만 처리) 0.73±0.12* 1.65±0.92** 7.50±0.27* 3.78±0.56** 12.98±1.20**
5-FU + 조성물1 1.03±0.15a 2.52±0.39a 8.38±0.36a 6.30±0.98b 20.92±2.23a
5-FU + 조성물4 1.15±0.20a 3.12±0.56b 8.63±0.41a 6.85±0.91b 23.58±2.54b
5-FU + 비교예1 0.87±0.13 2.02±0.33 8.03±0.34 4.53±0.77 15.31±2.07
5-FU + 비교예2 0.94±0.14 1.72±0.30 7.93±0.26 3.99±0.66 14.45±1.93
5-FU + 비교예3 0.77±0.12 2.10±0.31 7.67±0.31 5.03±0.72a 17.32±2.17
5-FU + 비교예4 1.00±0.16a 2.31±0.33a 8.01±0.38 5.20±0.95a 20.01±2.11a
5-FU + 비교예5 1.06±0.14a 2.82±0.33b 7.82±0.36 6.15±0.96b 20.32±2.34a
5-FU + 비교예6 1.10±0.15a 2.90±0.36b 8.48±0.34a 5.50±0.92a 17.37±2.70
5-FU + 비교예7 0.95±0.18 2.96±0.38b 8.40±0.37a 6.20±0.91b 20.88±2.37a
TABLE 3
Group PLT (10 6 / μl) WBC (10 3 / μl) RBC (10 6 / μl) IL-1ß (pg / mL) IFN-γ (pg / mL)
Normal 1.24 ± 0.25 3.52 ± 0.61 9.03 ± 0.43 7.25 ± 0.77 27.32 ± 2.32
Negative Control (5-FU only) 0.73 ± 0.12 * 1.65 ± 0.92 ** 7.50 ± 0.27 * 3.78 ± 0.56 ** 12.98 ± 1.20 **
5-FU + Composition 1 1.03 ± 0.15 a 2.52 ± 0.39 a 8.38 ± 0.36 a 6.30 ± 0.98 b 20.92 ± 2.23 a
5-FU + Composition 4 1.15 ± 0.20 a 3.12 ± 0.56 b 8.63 ± 0.41 a 6.85 ± 0.91 b 23.58 ± 2.54 b
5-FU + Comparative Example 1 0.87 ± 0.13 2.02 ± 0.33 8.03 ± 0.34 4.53 ± 0.77 15.31 ± 2.07
5-FU + Comparative Example 2 0.94 ± 0.14 1.72 ± 0.30 7.93 ± 0.26 3.99 ± 0.66 14.45 ± 1.93
5-FU + Comparative Example 3 0.77 ± 0.12 2.10 ± 0.31 7.67 ± 0.31 5.03 ± 0.72 a 17.32 ± 2.17
5-FU + Comparative Example 4 1.00 ± 0.16 a 2.31 ± 0.33 a 8.01 ± 0.38 5.20 ± 0.95 a 20.01 ± 2.11 a
5-FU + Comparative Example 5 1.06 ± 0.14 a 2.82 ± 0.33 b 7.82 ± 0.36 6.15 ± 0.96 b 20.32 ± 2.34 a
5-FU + Comparative Example 6 1.10 ± 0.15 a 2.90 ± 0.36 b 8.48 ± 0.34 a 5.50 ± 0.92 a 17.37 ± 2.70
5-FU + Comparative Example 7 0.95 ± 0.18 2.96 ± 0.38 b 8.40 ± 0.37 a 6.20 ± 0.91 b 20.88 ± 2.37 a
aP<0.05 vs 음성대조군; bP<0.01 vs 음성대조군; *P<0.05 vs 정상군; **P<0.01 vs 정상군 a P <0.05 vs negative control; b P <0.01 vs negative control; * P <0.05 vs normal group; ** P <0.01 vs normal
상기 정리된 결과에서 볼 수 있는 바와 같이, 혈소판(PLT) 수치에 있어서, 5-FU 만 처리했을 때에는 정상군에 비해 41%가 유의적으로 감소하는 것이 관찰되었다. 5-FU 처리 후, 본 발명의 건강기능성 식품용 조성물을 7일간 투여하였을 때에는, 혈소판 수치가 5-FU 만 처리한 군에 비해 41~58%의 유의적으로 상승된 수치를 보였다. 따라서 본 발명의 건강기능성 식품용 조성물의 투여에 의하여 정상군의 83~93% 수준으로 회복됨을 확인할 수 있었다.As can be seen from the above results, it was observed that 41% of platelet (PLT) levels were significantly reduced compared to the normal group when 5-FU alone. After 5-FU treatment, when the healthy functional food composition of the present invention was administered for 7 days, platelet levels were significantly increased by 41-58% compared to the 5-FU-only group. Therefore, it was confirmed that the 83 to 93% of the normal group was recovered by the administration of the health functional food composition of the present invention.
또한, 백혈구(WBC) 수치에 있어서, 5-FU 만 처리했을 때에는 정상군에 비해 53%가 유의적으로 감소함이 관찰되었다. 5-FU 처리 후, 본 발명의 건강기능성 식품용 조성물을 7일간 투여하였을 때에는, 백혈구 수치가 5-FU 만 처리한 군에 비해 53~89%의 유의적으로 상승된 수치를 보였다. 따라서 본 발명의 건강기능성 식품용 조성물의 투여에 의하여 정상군의 72~89% 수준으로 회복됨을 확인할 수 있었다.In addition, in the WBC level, only 5-FU treatment showed a significant decrease of 53% compared to the normal group. After 5-FU treatment, when the health functional food composition of the present invention was administered for 7 days, the leukocyte count was significantly increased by 53-89% compared to the 5-FU-treated group. Therefore, it was confirmed that the administration of the health functional food composition of the present invention to 72 ~ 89% of the normal group.
또한, 적혈구(WBC) 수치에 있어서, 5-FU 만 처리했을 때에는 정상군에 비해 15%가 유의적으로 감소함이 관찰되었다. 5-FU 처리 후, 본 발명의 건강기능성 식품용 조성물을 7일간 투여하였을 때에는, 적혈구 수치가 5-FU 만 처리한 군에 비해 12~15%의 유의적으로 상승된 수치를 보였다. 따라서 본 발명의 건강기능성 식품용 조성물의 투여에 의하여 정상군의 93~96% 수준으로 회복됨을 확인할 수 있었다.In addition, the erythrocyte (WBC) level was significantly reduced by 15% compared to the normal group when 5-FU alone. After 5-FU treatment, when the healthy functional food composition of the present invention was administered for 7 days, erythrocyte levels were significantly increased by 12-15% compared to the 5-FU-treated group. Therefore, it could be confirmed that the administration of the functional food composition of the present invention recovered to 93-96% of the normal group.
또한, IL-1ß수치에 있어서 5-FU 만 처리했을 때, 정상군에 비해 48%가 유의적으로 감소함이 관찰되었다. 5-FU 처리 후, 본 발명의 건강기능성 식품용 조성물을 7일간 투여하였을 때에는, IL-1ß수치가 5-FU만 처리한 군에 비해 67 ~ 81 %의 유의적으로 상승된 수치를 보였다. 따라서 본 발명의 조성물의 투여에 의하여 정상군의 87~ 94% 수준으로 회복됨을 확인할 수 있었다.In addition, when only 5-FU was treated in the IL-1ß value, a significant decrease of 48% was observed. After 5-FU treatment, when the health functional food composition of the present invention was administered for 7 days, the IL-1ß value was significantly increased by 67-81% compared to the 5-FU-only group. Therefore, the administration of the composition of the present invention was confirmed to recover to 87 ~ 94% of the normal group.
IFN-γ 수치에 있어서 5-FU 만 처리했을 때, 정상군에 비해 52%가 유의적으로 감소함이 관찰되었다. 5-FU 처리 후, 본 발명의 건강기능성 식품용 조성물을 7일간 투여하였을 때에는, IFN-γ 수치가 5-FU 만 처리한 군에 비해 61 ~ 82 %의 유의적으로 상승된 수치를 보였다. 따라서 본 발명의 조성물의 투여에 의하여 정상군의 77 ~ 86% 수준으로 회복됨을 확인할 수 있었다. When only 5-FU was treated in IFN-γ levels, a significant decrease of 52% was observed compared to the normal group. After 5-FU treatment, IFN- [gamma] levels were significantly increased by 61-82% compared to the 5-FU-treated group when the health functional food composition of the present invention was administered for 7 days. Therefore, the administration of the composition of the present invention was confirmed to recover to 77 ~ 86% level of the normal group.
종합해보면, 본 발명의 조성물은 항암치료제인 5-FU 투여에 따른 치료 후유증에 있어, 혈액의 주요 구성성분인 적혈구, 백혈구 및 혈소판의 조성을 회복시키는 효과 및 면역인자인 IL-1 및 IFN-γ 생산을 회복시키는 효과가 우수함을 알 수 있었다. 또한 항암제 투여에 의한 혈액의 조성 및 기능의 악화 현상은 항암치료 뿐만 아니라 외과적 수술 후 및 노약자에게서도 관찰되므로 상기 결과를 토대로 본 발명에 따른 건강기능성 식품용 조성물은 외과 수술 후나 노약자와 같이 건강이 쇠약해진 사람에게 효과적일 수 있다는 것을 유추할 수 있었다. Taken together, the composition of the present invention is effective in restoring the composition of erythrocytes, leukocytes and platelets, which are the major constituents of blood, in the treatment of sequelae following administration of 5-FU, an anticancer drug, and the production of IL-1 and IFN-γ, which are immune factors. It was found that the effect of recovering is excellent. In addition, the deterioration of the composition and function of blood by the administration of anticancer drugs is observed not only in chemotherapy but also in postoperative surgery and the elderly. Based on the above results, the health functional food composition according to the present invention is deteriorated after surgery or the elderly. It could be inferred that it could be effective for the deteriorated person.
<실시예 2>: 인체에서의 혈액조성, 항산화 방어력 저하의 회복 평가 < Example 2>: recovery evaluation of blood composition, antioxidant defense lowering in the human body
강도 높은 운동 스트레스는 적혈구의 생성 속도보다 파괴 속도를 높여 빈혈을 초래하며, 장기간의 고강도 트레이닝은 백혈구를 감소시켜 면역력을 저하시킨다. 즉, 장기간의 고강도 트레이닝에 의해서 운동능력은 향상되지만, 누적된 스트레스에 의하여 훈련기간 직후의 혈액학적 조성 및 기능은 환자의 경우와 매우 유사한 경향을 갖는다. 따라서 항암요법을 받은 환자, 수술 후의 환자 및 노환의 경우에 나타나는 공통적인 현상인 혈액 조성의 악화 및 혈액기능을, 일반 환자들에 대한 연구에 비해 훨씬 잘 제어된 실험조건 하에서 평가할 수 있다. 이에 따라 대학에 재학 중인 남자 싸이클 운동선수 40명을 대상으로 고강도 트레이닝이 필요한 동계 전지훈련 전후에 있어서, 본 발명의 조성물의 혈액조성 및 기능 회복 효과를 평가하였다. 이들은 학교 기숙사 생활을 통해 동일한 내용의 식단구성과 훈련일정에 참여하고 있으며 실험 참가 전 최근 1개월 이내에 약물복용의 경험이 없고 의학적 검진 이상이 없는 선수들을 대상으로 하였다. 대상자들은 무작위로 섭취 집단(n=20)과 비교 집단(n=20)으로 나누어졌다. Intensive exercise stress causes anemia by increasing the rate of destruction rather than the rate of red blood cell production, and long-term, high-intensity training reduces leukocytes and lowers immunity. In other words, exercise performance is improved by long-term, high-intensity training, but due to accumulated stress, hematological composition and function immediately after the training period tend to be very similar to those of patients. Therefore, the deterioration of blood composition and blood function, which is a common phenomenon in patients undergoing chemotherapy, postoperative patients and old age, can be evaluated under controlled conditions much better than in general patients. As a result, the blood composition and function recovery effects of the composition of the present invention were evaluated before and after winter cell training requiring high-intensity training for 40 male cycle athletes in college. They participated in the same diet and training schedule throughout the school dormitory and had no experience of taking medication and had no medical checkups within the last month prior to the experiment. Subjects were randomly divided into the intake group (n = 20) and the comparison group (n = 20).
모든 대상자들에게 연구의 목적과 의도를 사전에 충분히 설명하였고 실험기간 동안 피험자들은 어떠한 식이 요법에도 참가하지 않았으며 약물의 복용도 금지시켰다. All subjects were fully informed in advance of the purpose and intent of the study, and during the study period, subjects did not participate in any diet and were prohibited from taking the drug.
한 달간의 동계 전지훈련 기간에 맞추어 실험이 이루어졌으며 섭취집단은 제조예 1의 조성물2(하루 9캡슐, 캡슐당 450 mg)를 코치의 지도 하에 4주간 섭취하도록 하였다.The experiment was carried out in accordance with the one-month winter cell training period, and the intake group was to consume the composition 2 of Preparation Example 1 (9 capsules per day, 450 mg per capsule) for 4 weeks under the guidance of a coach.
실험예 1. 채혈 및 혈액 검사 Experimental Example 1. Blood collection and blood test
8시간 이상의 공복을 유지한 후 1회용 주사기를 이용하여 10㏄의 채혈을 실시하였다. 상완주정맥(antecubital vein)에서 채혈한 샘플을 EDTA 처리 튜브와 혈청분리용 튜브에 나누어 담은 후, 혈청은 3000 rpm에서 15분간 원심분리 후 상층에서 얻었고 전혈과 혈장에서 나머지 혈액 성분들을 분석하였다. After holding an empty stomach for 8 hours or more, a blood collection of 10 mm was performed using a disposable syringe. Samples collected from the antecubital vein were divided into EDTA treatment tubes and serum separation tubes. Serum was obtained from the upper layer after centrifugation at 3000 rpm for 15 minutes, and the remaining blood components were analyzed in whole blood and plasma.
혈액 세포 중 적혈구(RBC), 백혈구(WBC), 혈색소(Hb), 적혈구용적률(Hct)을 각각 측정하였고, 혈액의 항산화 방어력을 대표하는 혈중 항산화 효소 중 환원 글루타치온(glutathione; GSH)과 카탈라아제(catalase; CAT) 및 혈액의 산화 스트레스 정도를 나타내는 지질과산화 물질인 malondialdehyde(MDA)를 각각 측정하였다.Red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb), and red blood cell volume (Hct) were measured in blood cells, and reduced glutathione (GSH) and catalase among blood antioxidant enzymes representing the antioxidant defenses of blood. CAT) and malondialdehyde (MDA), a lipid peroxidant that indicates the degree of oxidative stress in the blood, were measured.
실험예 2. 환원 글루타치온 농도 측정 Experimental Example 2 Measurement of Reduced Glutathione Concentration
혈액 항산화 방어력의 지표인 환원글루타치온(GSH) 농도는 혈중 총 글루타치온 농도와 혈중 산화글루타치온 농도의 차로서 결정하였다. Reduced glutathione (GSH) concentration, which is an indicator of blood antioxidant defense, was determined as the difference between total glutathione level and blood glutathione level.
(환원 글루타치온 농도= 총 글루타치온 농도-산화글루타치온 농도)(Reduced glutathione concentration = total glutathione concentration-glutathione oxide concentration)
총 글루타치온 농도는 아래와 같이 측정하였다. Total glutathione concentration was measured as follows.
혈액에 6% 아세트산과 10%의 설포살리실산를 넣고 혼합하여 수분간 방치 후 5000 rpm으로 5분간 원심분리 하였다. 상층액을 재원심 분리하여 얻은 상층액을 희석하고 여기에 일정량의 NADPH(nicotinamide adenine dinucleotide phosphate, reduced form)와 DTNB(5,5'-dithio-bis-2-nitrobenzoicacid)를 혼합하여 35℃에서 5분간 방치하였다. GR(glutathion reductase, Sigma G3664) 50 ㎕를 넣어 반응을 일으킨 후 즉시 UV-spectrophotometer를 이용하여 412nm에서 2분간 흡광도를 측정한 후 GSH 기준 곡선에서 관찰된 기울기와 비교하여 총 글루타치온의 함량을 측정하였다.6% acetic acid and 10% sulfosalicylic acid were added to the blood, mixed, left for several minutes, and centrifuged at 5000 rpm for 5 minutes. The supernatant obtained by centrifugation of the supernatant was diluted and mixed with a predetermined amount of nicotinamide adenine dinucleotide phosphate (NADPH) and DTNB (5,5'-dithio-bis-2-nitrobenzoicacid) at 35 ° C. It was left for a minute. 50 μl of GR (glutathion reductase, Sigma G3664) was added to the reaction and immediately measured the absorbance at 412 nm using a UV-spectrophotometer. The total glutathione content was measured by comparing with the slope observed in the GSH reference curve.
산화글루타치온 (GSSG) 농도는 아래와 같이 측정하였다. Glutathione oxide (GSSG) concentration was measured as follows.
혈액에 6% 아세트산과 10%의 설포살리실산을 넣고 혼합하여 수 분 방치 후 5000 rpm으로 5분간 원심분리 하였다. 상층액을 재원심분리하여 얻은 상층액에 2-VP(2-vinylpyridine, Sigma 132292) 섞어 강하게 흔든 후 상온에서 1시간 방치하였다. 이것을 버퍼로 희석하고 여기에 일정량의 NADPH와 DTNB를 혼합하여 35℃에서 5분간 방치하였다. GR 50㎕를 넣어 반응을 일으킨 후 즉시 UV-spectrophotometer를 이용하여 412 nm에서 3분간 흡광도를 측정한 후 GSSG 기준 곡선에서 관찰된 기울기와 비교하여 산화된 글루타치온의 함량을 측정하였다.6% acetic acid and 10% sulfosalicylic acid were added to the blood, mixed and allowed to stand for several minutes, followed by centrifugation at 5000 rpm for 5 minutes. The supernatant obtained by recentrifugation was mixed with 2-VP (2-vinylpyridine, Sigma 132292) and shaken vigorously, and left at room temperature for 1 hour. This was diluted with a buffer, and a certain amount of NADPH and DTNB were mixed and left at 35 ° C for 5 minutes. After 50 μl of GR was added to the reaction, the absorbance was measured at 412 nm using a UV-spectrophotometer immediately, and then the content of oxidized glutathione was measured in comparison with the slope observed in the GSSG reference curve.
실험예 3. 카탈라아제(catalase)의 측정Experimental Example 3 Measurement of Catalase
혈액 항산화 방어력의 지표인 카탈라아제는 Molecular Probes사의 catalase assay kit(A-22180)를 이용하여 분석하였다. 혈청 속에 H2O2와 HRP(horseradish peroxidase)를 넣어 주게 되면 카탈라아제는 H2O2를 물로 환원시키는 반응을 하게 되고, HRP는 H2O2와 반응하여 resorufin이라는 형광물질을 생성하는 반응을 경쟁적으로 하게 되는 원리를 이용하였다. 카탈라아제의 활성도가 높으면 resorufin의 신호는 감소하게 된다. Resorufin의 흡광도는 570 nm에서 측정하였고 (카탈라아제)기준 곡선을 이용하여 농도를 산출하였다. 1U는 1 μ㏖의 H2O2를 환원시키는 효소 양으로 하였다. Catalase, an indicator of blood antioxidant defense, was analyzed using Molecular Probes' catalase assay kit (A-22180). When H 2 O 2 and HRP (horseradish peroxidase) are added to the serum, catalase reacts to reduce H 2 O 2 to water, and HRP reacts with H 2 O 2 to produce a fluorescent substance called resorufin. We used the principle of doing so. High catalase activity decreases the signal of resorufin. The absorbance of Resorufin was measured at 570 nm and the concentration was calculated using the (catalase) reference curve. 1U is the enzyme amount was reduced to the H 2 O 2 in 1 μ㏖.
실험예 4. MDA의 측정Experimental Example 4. Measurement of MDA
혈액 내 산화 스트레스의 지표인 MDA(malondialdehyde)을 측정하기 위하여 혈액을 원심분리 후 얻은 혈청에 10%의 TCA(트리클로로아세트산)을 넣고 끓는 물에서 30분간 끓인 다음 냉각시키고 3000 rpm에서 10분간 원심분리 하였다. 상층액을 취한 후 0.67% TBA(thiobarbitric acid)을 넣은 후 반응혼합물을 끓는 물에서 30분간 끓인 다음 냉각시키고 3000 rpm에서 10분간 원심분리 하였다. UV-spectrophotometer를 이용하여 535 nm에서 흡광도를 측정하였고, 기준 곡선은 malondialdehyde-bis를 이용하여 측정하였다. In order to measure MDA (malondialdehyde) which is an indicator of oxidative stress in blood, 10% of TCA (trichloroacetic acid) was added to serum obtained after centrifugation, boiled in boiling water for 30 minutes, cooled, and centrifuged at 3000 rpm for 10 minutes. It was. After taking the supernatant, 0.67% TBA (thiobarbitric acid) was added, the reaction mixture was boiled in boiling water for 30 minutes, cooled, and centrifuged at 3000 rpm for 10 minutes. The absorbance was measured at 535 nm using a UV-spectrophotometer, and the reference curve was measured using malondialdehyde-bis.
표 4
분석 항목 시험군 섭취 전 4주 섭취 후
RBC(106/㎣) 섭취군 4.72±0.28 4.88±0.22a
플라시보군 4.73±0.31 4.63±0.26
WBC(103/㎣) 섭취군 7.24±1.44 7.02±1.16a
플라시보군 7.19±1.80 5.73±1.25*
Hb(g/dL) 섭취군 14.41±0.83 15.06±0.73**a
플라시보군 14.36±0.68 14.47±0.72
Hct(%) 섭취군 42.42±2.50 44.43±2.10**
플라시보군 42.27±2.13 42.30±1.86
Table 4
Analysis item Test group Before intake After 4 weeks
RBC (10 6 / ㎣) Intake group 4.72 ± 0.28 4.88 ± 0.22 a
Placebo County 4.73 ± 0.31 4.63 ± 0.26
WBC (10 3 / ㎣) Intake group 7.24 ± 1.44 7.02 ± 1.16 a
Placebo County 7.19 ± 1.80 5.73 ± 1.25 *
Hb (g / dL) Intake group 14.41 ± 0.83 15.06 ± 0.73 ** a
Placebo County 14.36 ± 0.68 14.47 ± 0.72
Hct (%) Intake group 42.42 ± 2.50 44.43 ± 2.10 **
Placebo County 42.27 ± 2.13 42.30 ± 1.86
aP<0.05 vs 플라시보; *P<0.05 vs 섭취전; **P<0.01 vs 섭취전 a P <0.05 vs placebo; * P <0.05 vs before intake; ** P <0.01 vs before intake
상기 표 4에서 보는 바와 같이, 4주간의 동계 전지 훈련 이후, 적혈구(RBC) 수치는 비교집단이 약간 감소한 반면 본 발명의 조성물을 섭취한 집단은 유의성 있게 증가하였다. 또한 백혈구 (WBC)의 경우, 비교집단에서 유의하게 감소한 반면 섭취집단은 초기의 정상적 수준을 유지하는 것으로 나타났다. 따라서 본 발명의 조성물의 섭취가 면역력의 효과적인 회복에 기여하는 것을 잘 보여주고 있다. 또한 본 발명의 조성물을 섭취한 집단의 혈색소(Hb) 수치와 적혈구용적률(Hct) 수준이 유의하게 증가하였다. 따라서 섭취집단의 적혈구수의 증가와 더불어 본 발명의 조성물은 우수한 조혈작용을 가지고 있음을 알 수 있다. 결론적으로 본 발명의 조성물의 섭취는 조혈작용과 면역기능을 회복시키는 효과가 우수하다. As shown in Table 4 above, after 4 weeks of winter cell training, the red blood cell (RBC) level was significantly decreased in the group ingesting the composition of the present invention while the comparative group was slightly decreased. In the case of leukocytes (WBC), the control group showed a significant decrease while the intake group maintained the initial normal level. Thus it is well shown that ingestion of the composition of the present invention contributes to the effective recovery of immunity. In addition, hemoglobin (Hb) levels and red blood cell volume (Hct) levels of the populations of the present invention were significantly increased. Therefore, it can be seen that the composition of the present invention has an excellent hematopoietic action with an increase in the number of erythrocytes in the intake group. In conclusion, the ingestion of the composition of the present invention is excellent in the effect of restoring hematopoietic action and immune function.
표 5
분석 항목 시험군 섭취 전 4주 섭취 후
글루타치온(nmol/mL) 섭취군 1.21±0.27 2.17±0.41***a
플라시보군 1.10±0.23 1.67±0.63*
카탈라아제(U/mL) 섭취군 5.61±1.20 8.63±1.02***a
플라시보군 5.67±1.28 6.82±1.06
MDA(nmol/mL) 섭취군 2.55±0.73 2.78±0.91a
플라시보군 2.50±0.85 3.68±1.23*
Table 5
Analysis item Test group Before intake After 4 weeks
Glutathione (nmol / mL) Intake group 1.21 ± 0.27 2.17 ± 0.41 *** a
Placebo County 1.10 ± 0.23 1.67 ± 0.63 *
Catalase (U / mL) Intake group 5.61 ± 1.20 8.63 ± 1.02 *** a
Placebo County 5.67 ± 1.28 6.82 ± 1.06
MDA (nmol / mL) Intake group 2.55 ± 0.73 2.78 ± 0.91 a
Placebo County 2.50 ± 0.85 3.68 ± 1.23 *
aP<0.05 vs 플라시보; *P<0.05 vs 섭취전; ***P<0.001 vs 섭취전 a P <0.05 vs placebo; * P <0.05 vs before intake; *** P <0.001 vs before intake
상기 표 5에서 보는 바와 같이, 글루타치온의 혈액 농도에 있어서, 집단 (P<0.05)과, 기간 (P<0.001) 모두의 경우에 있어서 유의성있는 차이가 있었다. 두 집단 모두 장기적인 트레이닝 이후 글루타치온의 혈액 내 농도가 상승하였으나, 본 발명의 조성물을 섭취한 집단의 글루타치온 농도가 현저하게 크게 상승되었다. 카탈라아제의 혈액 농도 또한, 집단 (P<0.05)과, 기간 (P<0.001) 모두의 경우에 있어서 유의하게 차이가 있었다. 두 집단 모두 장기적인 트레이닝 이후 카탈라아제의 혈액 내 농도가 상승하였으나, 본 발명의 조성물을 섭취한 집단의 카탈라아제 농도가 현저하게 크게 상승되었다.As shown in Table 5, there was a significant difference in the blood concentration of glutathione in both the population (P <0.05) and the period (P <0.001). Both groups had elevated blood concentrations of glutathione after long term training, but significantly increased glutathione concentrations in the groups ingesting the compositions of the present invention. The blood concentration of catalase was also significantly different for both population (P <0.05) and duration (P <0.001). Both groups had elevated blood levels of catalase after long term training, but significantly increased catalase concentrations in the populations of the compositions ingesting the present invention.
한편, MDA의 수준에 있어서, 플라시보군은 유의적인 증가 (P<0.05)를 보여 주었으나 섭취군은 유의적인 증가를 보이지 않았다. 집단간의 차이에 있어서 섭취군에 비해 플라시보군이 유의적으로 높은 증가 현상을 보였다 (P<0.05). 장기간의 훈련의 피로가 지속적으로 체내에 산화적 스트레스로 남아 혈액 내 MDA 수치가 증가되는 조건에서 플라시보군에 비해 본 발명의 조성물을 섭취한 집단의 증가율이 낮은 것은, 본 발명의 조성물의 섭취가 혈액의 항산화 기능을 향상시켜 지질과산화를 억제한 결과이다. On the other hand, in the level of MDA, the placebo group showed a significant increase (P <0.05), but the intake group did not show a significant increase. In the difference between the groups, the placebo group showed a significantly higher increase than the intake group (P <0.05). In the condition that fatigue of long-term training is continuously oxidative stress in the body and the MDA level in the blood is increased, the increase rate of the group ingesting the composition of the present invention is lower than that of the placebo group. It is the result of suppressing lipid peroxidation by improving antioxidant function.
상기 결과로서, 본 발명의 조성물의 섭취가 극심한 스트레스 조건하에서 혈액의 항산화 기능을 회복시키고 혈액의 산화 스트레스를 효과적으로 줄여주는 것을 확인하였다. 따라서, 본 발명의 건강기능성 식품용 조성물은 항암요법이나 지병, 노환, 운동스트레스로부터 야기되는 각종 산화 스트레스 물질을 효과적으로 제거할 수 있는 효소를 회복시킴으로써 건강의 회복을 촉진할 수 있을 것으로 기대된다.As a result, it was confirmed that the ingestion of the composition of the present invention restores the antioxidant function of blood and effectively reduces the oxidative stress of blood under extreme stress conditions. Therefore, the health functional food composition of the present invention is expected to promote the recovery of health by restoring enzymes that can effectively remove various oxidative stress substances caused by anticancer therapy, chronic disease, senility, and exercise stress.

Claims (9)

  1. 콜라겐 30~90 중량%, 아마씨 3~60 중량%, 플로로탄닌 1~50 중량%, 칼슘 1~30 중량%, 철 0.1~3 중량%, 비타민 E 0.01~ 0.5 중량% 및 비타민 B 0.01~ 0.1 중량% 를 포함하는 건강기능성 식품용 조성물.30 to 90% by weight collagen, 3 to 60% by weight flaxseed, 1 to 50% by weight fluorotannin, 1 to 30% by weight calcium, 0.1 to 3% by weight iron, 0.01 to 0.5% by weight vitamin E and 0.01 to 0.1% by weight vitamin B Health functional food composition comprising a weight%.
  2. 제1항에 있어서, 레시틴 1~10 중량%, 리그난 0.005~3 중량%, 및 구리 0.01~ 0.2 중량%를 더 포함하는 건강기능성 식품용 조성물. According to claim 1, Lecithin 1 to 10% by weight, lignan 0.005 to 3% by weight, and 0.01 to 0.2% by weight of copper for health functional food composition.
  3. 제1항에 있어서, 상기 콜라겐은 생선류 또는 육류에서 유래하는 것을 특징으로 하는 건강기능성 식품용 조성물. According to claim 1, wherein the collagen is a health functional food composition, characterized in that derived from fish or meat.
  4. 제1항에 있어서, 상기 아마씨는 가루나 액체인 것을 특징으로 하는 건강기능성 식품용 조성물. The health functional food composition according to claim 1, wherein the flaxseed is powder or liquid.
  5. 제1항에 있어서, 상기 플로로탄닌은 에콜(eckol), 디에콜(dieckol), 6,6'-비에콜(6,6'-bieckol), 8,8'-비에콜(8,8'-bieckol), 2-O-(2,4,6-트리하이드록시페닐)-6,6'-비에콜(2-O-(2,4,6-trihydroxyphenyl)-6,6'-bieckol), 플로로퓨코퓨로에콜(phlorofucofuroeckol), 퓨코퓨로에콜(fucofuroeckol), 2-플로로에콜(2-phloroeckol), 7-플로로에콜(7-phloroeckol), 트리플로레톨(triphlorethol) 및 플로로탄닌 A(phlorotannin A)으로 구성되는 그룹에서 선택되는 1종 또는 2종 이상의 혼합물인 것인 건강기능성 식품용 조성물. The method of claim 1, wherein the phlorotannin is ecol, dieckol, 6,6'-bieckol, 8,8'-bieckol, 8,8 '. -bieckol), 2-O- (2,4,6-trihydroxyphenyl) -6,6'-biechol (2-O- (2,4,6-trihydroxyphenyl) -6,6'-bieckol) , Phlorofucofuroeckol, fucofuroeckol, 2-phloroeckol, 7-phloroeckol, triplehlorethol and floro Tannin A (phlorotannin A) is one or a mixture of two or more selected from the group consisting of health functional food composition.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 건강기능성 식품용 조성물은 혈액의 조성이나 혈액의 항산화기능을 정상치로 회복시키는 것을 특징으로 하는 건강기능성 식품용 조성물. The health functional food composition according to any one of claims 1 to 5, wherein the health functional food composition restores the blood composition and the antioxidant function of the blood to a normal value.
  7. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 건강기능성 식품용 조성물은 항암치료 과정 및 전후, 수술 전후, 지병, 과도한 운동, 과도한 정신적 스트레스 또는 노환으로 인한 체력저하의 경우에 사용되는 것을 특징으로 하는 건강기능성 식품용 조성물. The method according to any one of claims 1 to 5, wherein the health functional food composition is used in the case of anti-cancer treatment process before and after, before and after surgery, chronic disease, excessive exercise, excessive mental stress or deterioration due to aging. Health functional food composition, characterized in that.
  8. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 조성물은 정제, 캡슐제, 환제, 과립제 액상제제, 음료, 유동식, 죽, 빵, 바 또는 쿠키의 형태인 것을 특징으로 하는 건강기능성 식품용 조성물. The health functional food according to any one of claims 1 to 5, wherein the composition is in the form of tablets, capsules, pills, granular liquid preparations, beverages, liquids, porridges, breads, bars or cookies. Composition.
  9. 제1항의 건강기능성 식품용 조성물 100 중량부에 대하여 부형성분 1 내지 1000 중량부를 포함하는 것을 특징으로 하는 건강기능성 식품.The health functional food comprising 1 to 1000 parts by weight of the excipient component based on 100 parts by weight of the composition for health functional food of claim 1.
PCT/KR2012/000107 2011-01-13 2012-01-05 Composition for a functional food having the effect of restoring blood composition and function WO2012096475A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280005658.0A CN103384477B (en) 2011-01-13 2012-01-05 For having the composition of the functional food recovering blood constitute and function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0003566 2011-01-13
KR1020110003566A KR101266889B1 (en) 2011-01-13 2011-01-13 Functional food compositions having the recovery effect of blood composition and function

Publications (2)

Publication Number Publication Date
WO2012096475A2 true WO2012096475A2 (en) 2012-07-19
WO2012096475A3 WO2012096475A3 (en) 2012-11-29

Family

ID=46507547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000107 WO2012096475A2 (en) 2011-01-13 2012-01-05 Composition for a functional food having the effect of restoring blood composition and function

Country Status (3)

Country Link
KR (1) KR101266889B1 (en)
CN (1) CN103384477B (en)
WO (1) WO2012096475A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147044A1 (en) * 2018-01-25 2019-08-01 주식회사 헤마스 Composition for animal feed comprising phlorotannin as active ingredient and product for animal
CN113068836A (en) * 2021-05-14 2021-07-06 国家体育总局运动医学研究所 Food-derived peptide and carbohydrate compositions for reducing acute exercise stress

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220015403A1 (en) * 2018-12-05 2022-01-20 Botamedi Inc. Composition for improving flavor of food, containing phlorotannin as active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990066785A (en) * 1997-10-02 1999-08-16 아처 다니엘 미드랜드 캄파니 Isoflavones Preparation and Use
KR20040095125A (en) * 2003-05-06 2004-11-12 대한민국 (부경대학교총장) Composition comprising phlorotannins isolated from the extract of Ecklonia stolonifera Okamura having anti-oxidative activity
JP2008239619A (en) * 2007-02-28 2008-10-09 Fuji Chem Ind Co Ltd Peripheral blood circulation ameliorative composition
WO2010041832A2 (en) * 2008-10-07 2010-04-15 부경대학교 산학협력단 Antioxidant active composition containing an ishige okamurae-derived compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990066785A (en) * 1997-10-02 1999-08-16 아처 다니엘 미드랜드 캄파니 Isoflavones Preparation and Use
KR20040095125A (en) * 2003-05-06 2004-11-12 대한민국 (부경대학교총장) Composition comprising phlorotannins isolated from the extract of Ecklonia stolonifera Okamura having anti-oxidative activity
JP2008239619A (en) * 2007-02-28 2008-10-09 Fuji Chem Ind Co Ltd Peripheral blood circulation ameliorative composition
WO2010041832A2 (en) * 2008-10-07 2010-04-15 부경대학교 산학협력단 Antioxidant active composition containing an ishige okamurae-derived compound

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147044A1 (en) * 2018-01-25 2019-08-01 주식회사 헤마스 Composition for animal feed comprising phlorotannin as active ingredient and product for animal
CN113068836A (en) * 2021-05-14 2021-07-06 国家体育总局运动医学研究所 Food-derived peptide and carbohydrate compositions for reducing acute exercise stress

Also Published As

Publication number Publication date
KR101266889B1 (en) 2013-05-24
CN103384477B (en) 2015-09-16
WO2012096475A3 (en) 2012-11-29
CN103384477A (en) 2013-11-06
KR20120082196A (en) 2012-07-23

Similar Documents

Publication Publication Date Title
US10918678B2 (en) Faecalibacterium prausnitzii strain CNCM 1-4573 for the treatment and prevention of gastrointestinal inflammation
US20110052644A1 (en) Composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response
CN108420854B (en) Antifatigue composition for improving endurance performance
KR101492650B1 (en) Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor
CN113398144B (en) Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people
KR101356330B1 (en) Hepatic function remedial agent
WO2012096475A2 (en) Composition for a functional food having the effect of restoring blood composition and function
WO2016190566A9 (en) Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient
WO2017191856A1 (en) Antidiabetic effect of gypenoside 75
KR101775087B1 (en) A composition for the prevention or treatment of stress or depression containing mulberrofuran G, sanggenon G and sanggenol A
KR20130097537A (en) Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory
KR20180134161A (en) Composition for preventing, improving or depression or anxiety comprising tart cherry extract and fermented rice germ extract
WO2023140657A1 (en) Analysis of intestinal flora in liver transplant patients, transplantation status monitoring thereby, and immunomodulatory theragnosis composition
KR20180122380A (en) Pycalibacter sp.
KR20200070081A (en) Lactobacillus salivarius having anticariogenic activities and composition comprising the same
WO2023038258A1 (en) Novel lactobacillus gasseri lm1065 strain derived from breast milk, and composition for alleviating premenstrual syndrome comprising said strain or culture product thereof
EP2601960A1 (en) Anti-fatigue composition of plant material and preparation method, use and products thereof
KR102439576B1 (en) Composition of Nutrient Delivery System for Improving Brain Function
KR102123030B1 (en) A composition for improving diabetes or for use of antioxidant comprising yeast extract and a method for preparing the yeast extract
KR20200070080A (en) Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same
KR20070108291A (en) Food for the prevention or alleviation of allergy symptoms and method for the preparation thereof
WO2020109646A1 (en) Phascolarctobacterium faecium for use in the prevention and treatment of obesity and its comorbidities
WO2023210988A1 (en) Novel bifidobacterium bifidum hem972 strain, and composition for improving intestinal environment comprising same strain or culture of same
JP4606715B2 (en) Immune activity enhancer, and food and quasi drug containing the same
KR100583876B1 (en) Healthy food containing kiwifruit extract for diebetes patient&#39;s diet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12734477

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12734477

Country of ref document: EP

Kind code of ref document: A2